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The EDRS sample is a sentinel sample of 
people who regularly use ecstasy and other 
illicit stimulants recruited via social media, 
advertisement on websites and via word-of-
mouth in the capital cities of Australia. The 
results are not representative of all people 
who use illicit drugs, nor of use in the general 
population. Data were collected in 2021 
from April-August. Interviews in 2020 and 
2021 were delivered face-to-face as well as 
via telephone, due to COVID-19 
restrictions being imposed in various 
jurisdictions throughout the data 
collection period. This methodological 
change should be factored into all 
comparisons of data from the 2020 and 
2021 sample relative to previous years.  
Sample Characteristics 
In 2021, the national EDRS sample (n=774) 
differed in some ways to the sample in 2020. 
Despite these differences, the 2021 sample 
continued to comprise predominantly young 
(median 24; IQR=21-29) males (63%), most of 
whom held tertiary qualifications (60% 
completed post-school qualifications) and lived 
in a rental house/flat (60%) or resided with their 
parents/at their family home (26%) at the time 
of interview. Ecstasy and cannabis continued 
to be the drugs of choice, and cannabis and 
alcohol were the drugs used most often.  
COVID-19  
Over half (55%) of the sample had been tested 
for SARS-CoV-2, although few participants 
had received a positive diagnosis (n≤5). Over 
one-tenth (11%) reported that they had 
received at least one dose of the COVID-19 
vaccine at the time of interview.  
Ecstasy 
Whilst ecstasy capsules remained the most 
commonly used form of ecstasy, recent use 
declined significantly in 2021 (70%; p<0.001), 
as did ecstasy pills (42%; p<0.001) and ecstasy 
powder (26%; p<0.001). Recent use of crystal 
remained stable (53%). Frequency of use also 
significantly declined, with median days of ‘any’ 
ecstasy use dropping from 12 days in 2020 to 7 
days in 2021 (p<0.001), and weekly or more 
ecstasy use more than halving amongst recent 
consumers, from 27% in 2020 to 13% in 2021 
(p<0.001). Over three-quarters (76%) reported 
that their last ecstasy capsule contained crystal, 
whilst 27% reported that it contained powder. 
The median price for all four forms of ecstasy 
increased significantly in 2021. Significant 
changes were observed in the perceived purity 
(p=0.001) and availability (p<0.001) of ecstasy 
capsules, with participants less likely to report 
purity as ‘high’ and availability as ‘very easy’ in 
2021.  
Methamphetamine 
Methamphetamine use has been declining 
over time but remained stable between 2020 
and 2021, with 26% reporting any recent use 
in the latter year. Over one-quarter (28%) of 
those who had recently used 
methamphetamine reported weekly or more 
frequent use, a significant increase from 17% 
in 2020 (p=0.022). Whilst powder has 
historically been the most commonly used 
form of methamphetamine, recent use of 
powder (12%) dropped to below crystal (16%) 
for the first time in 2021. The vast majority of 
participants (93%) who had used crystal had 
recently smoked this form. Price, perceived 
purity and perceived availability of both 
powder and crystal methamphetamine 
remained stable between 2020 and 2021. 
Cocaine 
Recent use of cocaine increased significantly 
from 68% in 2020 to 80% in 2021 (p<0.001), 
the largest per cent observed since monitoring 
commenced. This increase was mostly driven 
by significant increases in TAS, VIC and NSW, 
although slight increases were observed 
across all jurisdictions. Frequency of use, 
however, remained stable in 2021, as did the 
per cent of recent consumers reporting weekly 
or more frequent use (7%). The price of a gram 
of cocaine significantly increased (p<0.001), 
and a significant change was observed in the 
perceived purity (p=0.006), whereby 
participants were less like to report ‘high’ purity. 
In contrast, a significant change was observed 
in the perceived availability of cocaine 
(p=0.002), with participants more likely to 
report it as being ‘very easy’ to obtain in 2021.  
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Cannabis 
Approximately four in five participants have 
reported any recent use of cannabis each 
year since monitoring began in 2003. In 2021, 
the per cent reporting recent use (84%) 
significantly decreased relative to 2020 (88%; 
p=0.024). Weekly or more frequent use of 
cannabis among recent consumers remained 
stable (64%; 62% in 2020), as did daily use 
(24%; 21% in 2020). Price and availability of 
hydroponic and bush cannabis remained 
stable relative to 2020, although a significant 
change in perceived potency for both 
hydroponic (p=0.001) and bush cannabis 
(p=0.001) was observed between 2020 and 
2021. Ten per cent of participants reported 
recent use of non-prescribed pharmaceutical 
CBD oil.  
Ketamine, LSD and DMT 
Recent use of ketamine significantly 
increased from 43% in 2020 to 52% in 2021 
(p<0.001), representing the largest per cent 
reporting recent use since the 
commencement of monitoring. Recent use of 
LSD remained stable (53% in 2021), while 
recent DMT use significantly increased, from 
13% in 2020 to 18% in 2021 (p=0.015). 
Frequency of use for all three substances 
remained low and stable. Perceived purity 
remained stable for both ketamine and LSD, 
whilst the price of ketamine significantly 
increased from $200 in 2020 to $220 in 2021 
(p<0.001). A significant change was observed 
in the perceived availability of ketamine 
(p=0.030) and LSD (p=0.034), with both drugs 
reported as easier to obtain in 2021.  
New Psychoactive Substances (NPS)  
Any NPS use, including plant-based NPS, has 
fluctuated over time, with 16% reporting 
recent use in 2021, stable from 2020 (15%). 
Two per cent of participants reported recent 
use of synthetic cannabinoids, a significant 
decrease from 4% in 2020 (p=0.019). 
Other Drugs 
Recent use of non-prescribed pharmaceutical 
stimulants significantly increased from 39% in 
2020 to 46% in 2021 (p=0.004), as did the per 
cent reporting any recent hallucinogenic 
mushroom (45%; 30% in 2020; p<0.001) and 
GHB/GBL/1,4-BD (9%; 6% in 2020; p=0.049) 
use. Alcohol and tobacco use were common, 
though both significantly decreased in 2021, 
with 96% reporting recent alcohol use (98% in 
2020; p=0.014) and 73% reporting recent 
tobacco use (83% in 2020; p<0.001). In 
contrast, recent use of e-cigarettes 
significantly increased in 2021 to 58% (39% in 
2020; p<0.001).  
Drug-Related Harms and Other Associated 
Behaviours 
On the last occasion of ecstasy or related drug 
use, 89% of participants in 2021 reported 
concurrent use of two or more drugs (including 
alcohol, tobacco and e-cigarettes). Almost four 
in five (77%) participants obtained an AUDIT 
score of eight or more (81% in 2020; p=0.025), 
indicative of hazardous alcohol use. Reported 
past year non-fatal stimulant overdose 
remained stable between 2020 (18%) and 
2021 (16%), whilst reported past year non-fatal 
alcohol overdose significantly decreased in 
2021 (15%; 21% in 2020; p=0.008). Reported 
past month injecting drug use remained low 
(11%), as did current drug treatment 
engagement (3%). The majority of the sample 
(82%) reported engaging in sexual activity in 
the past four weeks, of which 22% reported 
penetrative sex without a condom where they 
did not know the HIV status of their partner. 
Over one-third (36%) of the sample reported 
having a sexual health check-up in the past six 
months. A significant increase was observed in 
the per cent reporting a mental health problem 
in the past six months (58%; 52% in 2020; 
p=0.017). One-quarter (25%) of the sample 
reported driving while over the perceived legal 
limit of alcohol, and 39% reported driving within 
three hours of consuming an illicit or non-
prescribed drug, most commonly cannabis. 
Over one-third (36%) of the sample reported 
‘any’ crime in the past month, with drug-dealing 
(23%) and property crime (18%) remaining the 
main forms of criminal activity in 2021. Face-
to-face was the most popular means by which 
participants arranged the purchase of illicit or 
non-prescribed drugs in the past 12 months 
(72%; 67% in 2020; p=0.040), followed by 
social networking applications (71%).  
2021 SAMPLE CHARACTERISTICS
PAST 6 MONTH USE OF OTHER DRUGS
MENTAL HEALTH AND SEXUAL HEALTH BEHAVIOURS
OTHER RISK BEHAVIOURS
In 2021, 774 people from all 
Australian capital cities 
participated in EDRS interviews.
The median age in 2021 was 24 
(IQR = 21 - 29), and 63% 
identified as male.
In the 2021 sample, 45% were 
enrolled students, 22% were 
unemployed, and 27% were 
employed full time.
In the total sample, 39% reported 
driving a vehicle within 3 hours of 
consuming illicit drugs and 25% 
while over the legal limit of alcohol.
The most common drugs used prior 
to driving were cannabis (71%) and 
cocaine (21%).
The most commonly used 
combinations of drug classes were 
alcohol and MDMA (9%), followed by 
alcohol and cocaine (8%).
Participants were recruited on the 
basis that they had consumed
ecstasy or other illicit stimulants 
at least monthly in the past 6 
months.
In the total sample, 88% reported 
concurrent use of two or more 
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In the total sample, 58% 
self-reported a mental health issue 
and 35% had seen a mental health 
professional in the past 6 months. 
Of those who commented, the top 
three most common mental health 
issues reported were anxiety (71%), 
depression (62%) and PTSD (14%). 
Sexual risk behaviours among those 
who reported any sexual activity in 
the past four weeks (82%) and were 
able to comment.
In the total sample, 82% reported 
sexual activity in the past 4 weeks, 
and 36% had a sexual health check 
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Had penetrative sex without 
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Past 6 month use of ecstasy 
capsules, crystal, pills, and 
powder in 2021.
Of those who had recently 
consumed ecstasy, 13% used it 
weekly or more frequently.
Past 6 month use of any 
methamphetamine (26%), crystal 
(16%), powder (12%) and base 
(<5) in 2021.
Of people who had consumed 
cocaine in the last 6 months, 98%  
had snorted it. 
Past 6 month use of any cocaine 
increased significantly from 2020 
(68%) to 2021 (80%).
Of those who had recently 
consumed methamphetamine, 
28% used it weekly or more 
frequently.
93% of people who had recently 
used crystal smoked it. Of those 
who had recently used powder, 78% 
snorted it.
Median amounts of ecstasy
consumed in a 'typical' session 
using each form. 
Of people who had consumed 
cocaine recently, 7% reported 
weekly or more frequent use.
Past 6 month use of any cannabis 
decreased from 88% in 2020 to 
84% in 2021.
Of people who had consumed 
cannabis in the last 6 months, 
95% had smoked it. 
Of those who had consumed
cannabis recently, 64% reported 
weekly or more frequent use.
Of those who could comment
75% perceived ecstasy capsules 
to be 'easy' or 'very easy' to 
obtain, 
Of those who could comment
82% perceived crystal 
methmphetamine to be ‘easy’ 
or ‘very easy’ to obtain. 
Of those who could comment
77% perceived cocaine to be 
‘easy’ or ‘very easy’ to obtain.
Of those who could comment
90% perceived hydro to be 
‘easy’ or ‘very easy’ to obtain.
13%
M T SFTW S
2 Capsules
2 Pills
0.30 grams of crystal
0.30 grams of powder
75%
Capsules were easy or 
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The EDRS interviews are conducted annually with a sentinel sample 
of people who regularly use ecstasy and other stimulants, recruited 
from all capital cities of Australia (n=774 in 2021). The results from the 
EDRS interviews are not representative of all people who consume 
illicit drugs, nor of illicit drug use in the general population, but this is 
not the aim of these data. Rather, these data are intended to provide 
evidence indicative of emerging issues that warrant further monitoring. 
These findings should be interpreted alongside analyses of other data 
sources for a more complete profile of emerging trends in illicit drug 
use, market features, and harms in Australia.    
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Background 
The Ecstasy and Related Drugs Reporting System (EDRS) is an illicit drug monitoring system which 
has been conducted in all states and territories of Australia since 2003, and forms part of Drug Trends. 
The purpose is to provide a coordinated approach to monitoring the use, market features, and harms 
of ecstasy and related drugs. This includes drugs that are routinely used in the context of 
entertainment venues and other recreational locations, including ecstasy, methamphetamine, 
cocaine, new psychoactive substances, LSD (d-lysergic acid), and ketamine.  
The EDRS is designed to be sensitive to emerging trends, providing data in a timely manner rather 
than describing issues in extensive detail. It does this by studying a range of data sources, including 
data from annual interviews with people who regularly use ecstasy and other illicit stimulants and from 
secondary analyses of routinely-collected indicator data. This report focuses on the key findings from 
the annual interview component of the EDRS.  
Methods 
EDRS 2003-2019 
Full details of the methods for the annual interviews are available for download. To briefly summarise, 
since the commencement of monitoring up until 2019, participants were recruited primarily via internet 
postings, print advertisements, interviewer contacts, and snowballing (i.e., peer referral). Participants 
had to: i) be at least 17 years of age (due to ethical constraints) (16 years of age in WA), ii) have used 
ecstasy or other stimulants (including: MDA, methamphetamine, cocaine, mephedrone or other 
stimulant NPS) at least six times during the preceding six months; and iii) have been a resident of the 
capital city in which the interview took place for ten of the past 12 months. Interviews took place in 
varied locations negotiated with participants (e.g., research institutions, coffee shops or parks), and 
were conducted using REDCap (Research Electronic Data Capture), a software program to collect 
data on laptops or tablets. Following provision of written informed consent and completion of a 
structured interview, participants were reimbursed $40 cash for their time and expenses incurred.  
EDRS 2020-2021: COVID-19 Impacts on Recruitment and Data Collection 
Given the emergence of COVID-19 and the resulting restrictions on travel and people’s movement in 
Australia (which first came into effect in March 2020), face-to-face interviews were not always possible 
due to the risk of infection transmission for both interviewers and participants. For this reason, all 
methods in 2020 were similar to previous years as detailed above, with the exception of: 
1. Means of data collection: Interviews were conducted via telephone or via videoconferencing 
across all jurisdictions in 2020; 
2. Means of consenting participants: Participants consent to participate was collected verbally 
prior to beginning the interview; 
3. Means of reimbursement: Once the interview was completed via REDCap, participants were 
given the option of receiving $40 reimbursement via one of three methods, comprising bank 
transfer, PayID or gift voucher; and 
4. Age eligibility criterion: Changed from 17 years old (16 years old in WA) to 18 years old. 
In 2021, a hybrid approach was used with interviews conducted either face-to-face (whereby 
participants were reimbursed with cash) or via telephone/videoconference (with participants 
reimbursed via bank transfer or other electronic means). Face-to-face interviews were the preferred 
methodology, however the introduction of restrictions by various jurisdictional governments 
throughout the recruitment period, combined with hesitancy from some participants to meet face-to-
face, meant that telephone interviews were conducted when required (i.e., in accordance with 
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government directives) or when requested by participants. Consent was collected verbally for all 
participants. 
Almost all jurisdictions experienced some trouble recruiting participants in 2021. While it is difficult to 
provide a definitive reason for this, it is possible that this was reflective of a reduction in ecstasy and 
other illegal stimulant use due to ongoing government restrictions, and the cancellation of many music 
festivals and events in 2020-21. The recruitment period was therefore extended until 13 August 2021. 
Further, in some jurisdictions, there was an increase in people not meeting the residency criteria (i.e., 
residence in the capital city in which the interview took place for at least ten out of the past 12 months), 
and this criterion was eased mid-way through data collection to include residency for six out of the 
past 12 months. 
A total of 774 participants were recruited across capital cities nationally (April-August, 2021). The 
sample sizes recruited from the capital city in each jurisdiction were: Sydney, NSW n=99; Melbourne, 
VIC n=100; Adelaide, SA n=100; Canberra, ACT n=100; Hobart, TAS n=102; Brisbane and Gold 
Coast, QLD n=73; Darwin, NT n=100; and Perth, WA n=100. Of this number, 325 interviews were 
conducted via telephone/videoconference: Sydney, NSW n=41; Melbourne, VIC n=72; Adelaide, SA 
n=35; Canberra, ACT n=49; Hobart, TAS n=19; Brisbane and Gold Coast, QLD n=29; Darwin, NT 
n=60; and Perth, WA n=20. 
Ten per cent of the 2021 sample had taken part in the 2020 interview (8% of the 2020 sample had 
taken part in the 2019 interview; p=0.188). 
Data Analysis  
For normally distributed continuous variables, means and standard deviations (SD) are reported; for 
skewed data (i.e., skewness > ±1 or kurtosis > ±3), medians and interquartile ranges (IQR) are 
reported. Tests of statistical significance have been conducted between estimates for 2020 and 2021, 
noting that no corrections for multiple comparisons have been made and thus comparisons should be 
treated with caution. Values where cell sizes are ≤5 have been suppressed with corresponding 
notation (zero values are reported). References to ‘recent’ use and behaviours refers to the past six-
month time period.  
 
Interpretation of Findings 
Caveats to interpretation of findings are discussed more completely in the methods for the annual 
interviews but it should be noted that these data are from participants recruited in capital cities, and 
thus do not reflect trends in regional and remote areas. Further, the results are not representative of 
all people who consume illicit drugs, nor of illicit drug use in the general population, but rather are 
intended to provide evidence indicative of emerging issues that warrant further monitoring.  
This report covers a subset of items asked of participants and does not include jurisdictional-level 
results beyond estimates of recent use of various substances (included in jurisdiction outputs; see 
below), nor does it include implications of findings. These findings should be interpreted alongside 
analyses of other data sources for a more complete profile of emerging trends in illicit drug use, market 
features, and harms in Australia (see section on ‘Additional Outputs’ below for details of other outputs 
providing such profiles). 
Differences in the methodology, and the events of 2020-21, must be taken into consideration when 
comparing 2020-21 data to previous years, and treated with caution.  
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Additional Outputs 
Infographics from this report are available for download. There are a range of outputs from the EDRS 
which triangulate key findings from the annual interviews and other data sources, including 
jurisdictional reports, bulletins, and other resources available via the Drug Trends webpage. There 
are also results from the Illicit Drug Reporting System (IDRS), which focus more so on the use of illicit 
drugs via injection. 
Please contact the research team at drugtrends@unsw.edu.au with any queries, to request additional 
analyses using these data, or to discuss the possibility of including items in future interviews. 







Participants were asked questions about select sociodemographic 
characteristics, as well as key drug use characteristics of interest. 




In 2021, the national EDRS sample differed in various ways to the sample in 2020 (Table 1). It is 
difficult to ascertain whether some of these changes (e.g., current accommodation and current 
employment) are a consequence of changes in the methodology, resulting in a slightly different 
sample being recruited, or whether it is a result of current events surrounding COVID-19.   
A significant change was observed in gender in 2021 (p=0.005), with over three-fifths (63%) of the 
sample identifying as male (61% in 2020) and one-third (34%) identifying as female (38% in 2020). 
Fewer participants (3%) identified as non-binary (1% in 2020). The median age of the sample was 24 
years (IQR=21-29), a significant increase from 22 years in 2020 (IQR=19-27; p<0.001).  
A significant change was observed in participants’ living situation (p<0.001), whereby three-fifths 
(60%) of participants reported living in a rented house/flat (50% in 2020), with most of the remaining 
participants living with their parents/in their family home (26%; 40% in 2020).  
The mean years of school remained stable relative to 2020, though a significant increase was 
observed in the percentage of participants who reported having a post-school qualification (60%; 51% 
in 2020; p<0.001).  
A significant change was observed in current employment status (p<0.001); over one-quarter (27%) 
reported being employed full-time (26% in 2020) and 22% reported being unemployed at the time of 
interview, a decrease from 35% in 2020. Furthermore, over two-fifths (45%) reported being employed 
on a part time/casual basis at the time of interview, an increase from 35% in 2020. 
Table 1: Demographic characteristics of the sample, nationally and by jurisdiction, 2020-2021 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=805 N=774 N=99 N=100 N=100 N=102 N=100 N=100 N=100 N=73 
 2020 2021         






















% Gender  **         
Female 38 34 29 34 26 34 42 32 34 38 
Male 61 63 67 64 67 62 57 64 65 60 
Non-binary 1 3 - - 7 - - - - - 
% Aboriginal and/or 
Torres Strait Islander 4 6 - 10 - 9 - - 10 - 
% Sexual identity  ***         
Heterosexual 83 73 75 69 64 77 70 77 84 68 
Homosexual 3 4 - - - - - - - - 
Bisexual 10 14 13 17 11 11 23 8 11 22 
Queer 2 6 8 7 17 6 - 6 - - 
Different identity 1 2 0 - 6 - - - - 0 
Mean years of school 
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 National NSW ACT VIC TAS SA WA NT QLD 
% Post-school 
qualification(s)^  51 60*** 52 55 69 69 62 54 70 49 
% Current 
employment status  ***         
Employed full-time 26 27 28 27 18 29 20 30 42 21 
Part time/casual 35 45 48 39 51 43 47 54 34 44 
Self-employed  5 6 8 10 8 - - - - - 
Students# 47 45 63 45 42 44 42 59 22 48 
Unemployed  35 22 15 24 23 24 29 12 21 29 
Current median 






























accommodation  ***         
Own house/flat 5 6 - 8 - 15 - 7 - - 
Rented house/flat 50 60 71 64 75 49 49 46 58 67 
Parents’/family home 40 26 26 15 19 28 40 46 13 19 
Boarding house/hostel 2 4 0 - - 0 - 0 21 - 
Public Housing 1 2 - - 0 - - 0 - - 
No fixed address+ 1 2 0 - - - - 0 - - 
Other 0 1 0 - 0 - 0 - - 0 
Note. ^ Includes trade/technical and university qualifications. # ‘students’ comprised participants who were currently studying for either 
trade/technical or university/college qualifications. + No fixed address included ‘couch surfing and rough sleeping or squatting.  – Per cent 
suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021 for the national sample.  
 
There was a significant change in drug of choice in 2021 compared to 2020 (p=0.020), with small 
declines in the per cent of participants who nominated ecstasy (24%; 29% in 2020) or cannabis (23%; 
26% in 2020) as their drug of choice (Figure 1). A significant change was also observed for the drug 
used most often in the past month (p=0.015). Specifically, there was a decrease in the per cent of 
participants who reported that cannabis was the drug used most often in the month preceding 
interview (36%; 42% in 2020), with an inverse increase in those who reported that alcohol was the 
drug used most often (31%; 27% in 2020) (Figure 2).  
Just over one-tenth (12%) of the sample reported weekly or more frequent ecstasy use, a significant 
decrease from 27% in 2020 (p<0.001). In contrast, weekly or more frequent methamphetamine use 
significantly increased in 2021 (7%; 4% in 2020; p=0.014), while weekly or more frequent use of 
cannabis remained stable (54%; 55% in 2020; p=0.835) (Figure 3). 
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Figure 1: Drug of choice, nationally, 2003-2021 
  
Note. Participants could only endorse one substance. Substances listed in this figure are the primary endorsed; nominal percentages have 
endorsed other substances. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021.      
 
Figure 2: Drug used most often in the past month, nationally, 2011-2021 
 
 
Note. Participants could only endorse one substance. Substances listed in this figure are the primary endorsed; nominal percentages have 
endorsed other substances. Data are only presented for 2011-2021 as this question was not asked in 2003-2010. *p<0.050; **p<0.010; 
***p<0.001 for 2020 versus 2021. 
 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021*
Ecstasy 52 51 51 45 39 37 42 37 27 32 32 36 30 36 36 36 32 29 24
Cannabis 12 13 12 15 14 13 17 16 20 19 23 25 29 21 28 26 26 26 23
Alcohol 3 6 5 9 13 15 11 12 11 15 18 12 15 15 11 7 8 11 11























2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021*
Ecstasy 19 19 15 25 17 20 16 21 21 13 11
Cannabis 31 30 33 32 41 33 43 38 36 42 36
Alcohol 25 32 39 30 34 35 33 25 29 27 31























Ecstasy and Related Drugs Reporting System 2021 
 
  14 
Figure 3: Weekly or more frequent substance use in the past six months, nationally, 2003-2021 
 
Note. Computed from the entire sample regardless of whether they had used the substance in the past six months. Significance for 2020 




2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Ecstasy 33 37 35 31 27 26 30 23 28 27 26 26 24 25 29 27 28 27 12
Cannabis 55 51 52 50 48 42 48 45 58 54 54 50 60 65 61 56 56 55 54
Methamphetamine 23 24 20 19 9 7 6 13 11 7 9 7 7 4 6 7 4 7
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Participants were asked about COVID-19 testing, diagnosis and 
vaccination, as well as engagement in health precautions.  
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COVID-19 
Background  
The first COVID-19 diagnosis occurred in Australia on 25 January 2020, with a rapid increase in cases 
throughout March (peak 455 cases 28 March 2020) which declined shortly thereafter (<20 cases per 
day nationally from 20 April 2020). There was a resurgence in cases from late June 2020, largely 
based in Victoria (peak 686 cases 5 August 2020), which subsequently declined from September 
onwards (<20 cases per day from 23 September 2020) (Figure 4). The third wave of cases occurred 
from late June 2021 onwards, largely in NSW (peak 1293 cases 30 August 2021, not including cases 
from 1 September 2021 onwards) and a couple of months later in VIC (peak 86 cases 29 August 
2021, not including cases from 1 September 2021 onwards). The number of cases in other 
jurisdictions during this third wave did not exceed 30 cases per day (as of 31 August 2021).  
As a nation of federated states and territories, public health policy including restrictions on movement 
and gatherings varies by jurisdiction. However, restrictions on gatherings were implemented across 
jurisdictions from early March 2020; by the end of March, Australians could only leave their residence 
for essential reasons. These restrictions were eased across May-June 2020, again with variation 
across jurisdictions (notably, significant restrictions being enforced again in Victoria from July-October 
2020). Restrictions were re-introduced in Victoria from 27 May to 10 June, 2021, and in NSW from 26 
June 2021 onwards, with other jurisdictions (VIC, SA, QLD and ACT) introducing restrictions shortly 
thereafter.  
Notably, most of the 2021 EDRS surveys occurred before the most recent wave of cases and 
before subsequent restrictions were introduced in some jurisdictions. However, Figure 4 serves 
to illustrate how COVID-19 restrictions throughout 2020-2021 may have impacted substance use, 
particularly those used in the context of entertainment venues and other recreational locations (which 
were often closed throughout periods of restrictions and beyond). 
Figure 4: Timeline of COVID-19 in Australia and EDRS data collection period, 2020-2021 
 
Notes: Data obtained from http://www.covid19data.com.au. Only lockdowns of >7 days and affecting at least an entire city are displayed. 
*National stay-at-home orders began lifting dependent on jurisdiction from May 1 2020. ^NSW lockdown 26 June 2021 onwards; VIC 
lockdowns 14 July-27 July 2021 and 5 August 2021 onwards; SA lockdown 20 July-27 July; Southeast QLD lockdown 31 July-8 August 
2021; ACT lockdown 12 August 2021 onwards. 
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COVID-19 Testing and Diagnosis 
In 2021, over half (55%) of the sample had been tested for SARS-CoV-2 by the time of interview (9% 
in 2020), with few participants having been diagnosed with the virus (n≤5; numbers are suppressed). 
When asked how worried they were currently about contracting COVID-19, 29% of participants 
reported some level of concern: one-fifth (21%) responded that they were ‘slightly’ concerned, 7% 
reported ‘moderately’, 1% reported ‘very’ and no participants reported being ‘extremely’ concerned 
(Figure 5). Furthermore, 72% of participants reported that they would be concerned about their health 
if they did contract COVID-19, with 30% reporting they would be ‘slightly’ concerned, 22% reporting 
‘moderately’, 14% reporting ‘very’ and 5% reporting that they would be ‘extremely’ concerned.  
Fourteen per cent of the sample reported quarantining for at least fourteen days due to a possible 
test or possible exposure (since January 2020), with 1% quarantining in the month prior to interview, 
3% two-six months prior to interview, and 5% 7-12 months prior to interview. At the time of interview, 
over one-tenth (11%) reported that they had received at least one dose of the COVID-19 vaccine.   
Figure 5: Current concern related to contracting COVID-19, nationally, 2020-2021 
 
Note. The response ‘Don’t know’ was excluded from analysis. Data labels have been removed from figures with small cell size (i.e., n≤5 
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COVID-19 Related Health Behaviours  
Participants were asked about COVID-19 related health precautions that they had engaged in during 
the four weeks prior to interview (Figure 6). In 2021, participants most commonly reported wearing a 
face mask (68%; 27% in 2020), keeping distance from other people (53%; 73% in 2020) and changing 
or cancelling travel plans (28%; 49% in 2020).  
Figure 6: Health precautions related to COVID-19 in the past four weeks, nationally, 2020-2021 
Note. The response ‘Don’t know’ was excluded from analysis Data labels have been removed from figures with small cell size (i.e., n≤5 but 



























0 20 40 60 80 100
Stopped working at all
Seeking advice from a medical professional
Purchasing additional medical supplies
Working from home
Wearing a facemask
Purchasing additional household supplies
Self-isolated (stayed at home)
Changing or cancelling travel plans
Cancelling personal gatherings
Avoiding public transport
Avoiding public spaces and public events




Ecstasy and Related Drugs Reporting System 2021 
 













Participants were asked about their recent (past six month) use of 
various forms of ecstasy (3,4-methylenedoxymethamphetamine), 
including pills, powder, capsules, and crystal. 
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Patterns of Consumption (any ecstasy) 
Recent Use (past 6 months) 
The vast majority of participants (95%) reported any recent use of ecstasy in 2021, although this was 
a significant decline relative to 2020 (99%; p<0.001). Consistent with the previous two years, capsules 
were the most commonly used form of ecstasy in the past six months. Whilst pills have historically 
(2003-2018) been the primary form of ecstasy used, recent use of crystal overtook recent use of pills 
for the second year running. Powder remained the least commonly used form of ecstasy, consistent 
with the entirety of the reporting period (Figure 7).  
Frequency of Use  
Participants reported using ecstasy (in any form) on a median of 7 days (IQR=5-15; n=737), a 
significant decrease from 12 days in 2020 (IQR=7-24; p<0.001) (Figure 8). Among those that reported 
recent use and commented (n=737), weekly or more frequent use of any form of ecstasy decreased 
from 27% in 2020 to 13% in 2021 (p<0.001). 
 




Note. Up until 2012, participant eligibility was determined based on any recent ecstasy use; subsequently it has been expanded to broader 
illicit stimulant use. Data collection for powder started in 2005, capsules in 2008 and crystal in 2013. Significance for 2020 versus 2021 
presented in figure; *p<0.050; **p<0.010; ***p<0.001. 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Pills 100 100 100 100 100 100 100 98 97 95 96 92 85 82 78 75 67 53 42
Capsules 19 27 47 53 53 50 53 60 60 71 72 77 83 70
Crystal 39 49 52 57 67 62 63 57 53
Powder 21 19 18 11 14 17 26 25 28 24 22 21 30 31 29 35 26
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Figure 8: Median days of any ecstasy and ecstasy pills, powder, capsules and crystal use in the past 
six months, nationally, 2003-2021 
 
 
Note. Up until 2012, participant eligibility was determined based on any recent ecstasy use; subsequently it has been expanded to broader 
illicit stimulant use. Data collection for powder started in 2005, capsules in 2008 and crystal in 2013. Median days computed among those 
who reported past 6-month use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 20 days to 
improve visibility of trends. Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; ***p<0.001. 
 
Table 2: Past six month use of ecstasy pills, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 100 100 100 100 100 100 100 100 
2004 100 100 100 100 100 100 100 100 
2005 100 100 100 100 100 100 100 100 
2006 100 100 100 100 100 100 100 100 
2007 100 100 100 100 100 99 100 100 
2008 100 100 100 100 100 100 100 100 
2009 100 100 100 100 99 100 100 100 
2010 99 99 98 96 99 100 100 98 
2011 99 100 90 95 100 100 100 99 
2012 99 94 92 92 98 100 67 95 
2013 99 96 86 93 98 99 96 99 
2014 89 91 90 92 96 98 99 81 
2015 69 56 84 99 94 99 98 86 
2016 52 70 93 95 96 98 90 67 
2017 42 79 83 93 71 93 86 78 
2018 41 80 77 88 56 92 90 76 
2019 40 70 74 74 62 68 92 56 
2020 41 55 69 74 52 25 63 43 
2021 17*** 36** 47** 55** 54 37 56 27 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Pills 12 15 15 12 12 12 12 12 12 12 11 10 10 10 8 8 6 5 4
Capsules 2 2 3 4 4 3 4 5 5 6 6 8 7 5
Crystal 3 5 5 6 6 5 6 6 5
Powder 2 2 2 3 2 3 4 4 3 4 4 4 5 3 4 4 4

















Ecstasy and Related Drugs Reporting System 2021 
 
  22 
Table 3: Past six month use of ecstasy capsules, by jurisdiction, 2008-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2008 24 23 18 18 16 28 9 17 
2009 33 6 48 48 10 15 31 27 
2010 35 37 65 81 38 14 89 42 
2011 55 39 64 80 34 11 64 57 
2012 57 61 67 75 29 32 25 52 
2013 59 43 69 53 26 48 27 67 
2014 76 56 66 49 37 51 32 53 
2015 64 69 76 50 49 65 44 62 
2016 68 72 84 40 55 54 44 64 
2017 76 67 90 60 81 61 57 72 
2018 77 74 87 62 58 76 74 72 
2019 82 81 90 62 64 84 76 78 
2020 88 91 78 73 83 83 90 78 
2021 82 76** 70 67 53*** 67* 82 64 
Note. Data collection for capsules started in 2008. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Table 4: Past six month use of ecstasy crystal, by jurisdiction, 2013-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2013 28 71 51 48 25 34 50 23 
2014 61 54 64 29 36 58 43 45 
2015 68 57 54 36 41 51 65 42 
2016 81 52 59 33 63 59 43 68 
2017 75 75 43 47 69 78 71 78 
2018 64 60 57 53 79 51 69 67 
2019 68 72 52 48 78 64 54 65 
2020 47 71 42 57 59 61 51 71 
2021 62* 36*** 47 66 49 63 38 63 
Note. Data collection for crystal started in 2013. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
Table 5: Past six month use of ecstasy powder, by jurisdiction, 2005-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2005 15 24 27 11 31 27 14 20 
2006 8 19 35 13 27 9 8 31 
2007 20 8 38 5 28 11 11 18 
2008 15 7 27 6 11 9 - 6 
2009 11 14 24 12 9 10 20 17 
2010 7 14 34 21 19 6 15 20 
2011 21 23 30 26 29 7 27 32 
2012 20 35 31 30 11 26 17 31 
2013 29 20 51 20 16 25 18 36 
2014 15 13 43 20 18 20 26 36 
2015 19 22 46 15 14 18 15 22 
2016 15 12 51 28 21 13 22 34 
2017 21 32 34 24 44 36 20 28 
2018 18 23 45 41 27 24 42 27 
2019 18 30 20 28 41 30 42 22 
2020 33 35 44 37 37 27 35 31 
2021 25 26 21** 40 22* 17 38 19 
Note. Data collection for powder started in 2005. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
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Patterns of Consumption (by form) 
Ecstasy Pills 
Recent Use (past 6 months): Reported recent 
use was at its lowest in 2021 (42%), down from 
53% in 2020 (p<0.001) (Figure 7). This decline 
was most prominent in NSW and VIC, as well 
as TAS and QLD (Table 2). 
Frequency of Use: Of those who had recently 
consumed ecstasy pills and commented 
(n=324), ecstasy pills were used on a median 
of 4 days (IQR=2-9) in the six months 
preceding interview, a significant decline 
relative to 2020 (5 days; IQR=2-12; p=0.002) 
(Figure 8). The percentage reporting weekly or 
greater use of ecstasy pills remained stable at 
8% in 2021 (11% in 2020; p=0.208). 
Routes of Administration: Among 
participants who had recently consumed 
ecstasy pills and commented (n=323), the 
most common route of administration reported 
by consumers was swallowing (96%; 96% in 
2020), followed by snorting (34%; 29% in 2020; 
p=0.104): this is consistent with previous 
years. Few participants reported recent 
shelving/shafting (2%; 3% in 2020; p=0.663). 
Quantity: Of those who reported recent use 
and responded (n=321), the median number of 
pills used in a ‘typical’ session was two (IQR=1-
3) in 2021 (2 pills in 2020; IQR=1-3; p=0.411). 
Of those who reported recent use and 
responded (n=321), the median maximum 
number of pills used was three (IQR=2-5; 3 pills 
in 2020; IQR=2-5; p=0.492). 
Ecstasy Capsules 
Recent Use (past 6 months): Capsules 
remained the most common form of ecstasy 
used in 2021. Nevertheless, a decline was 
observed, with 70% of the total sample 
reporting any recent use (83% in 2020; 
p<0.001) (Figure 7). This decline was most 
noticeable in SA, WA and the ACT (Table 3). 
Frequency of Use: Of those who recently 
consumed ecstasy capsules and commented 
(n=543), capsules were used on a median of 5 
days (IQR=3-9), a decline from 7 days (IQR=3-
12) in 2020 (p<0.001) (Figure 8). Six per cent 
reported weekly or more frequent use, a 
significant decrease relative to 2020 (13%; 
p<0.001). 
Routes of Administration: Among 
participants who had recently consumed 
ecstasy capsules and commented (n=544), 
swallowing remained the main route of 
administration (97% of consumers in 2021; 
96% in 2020; p=0.537). Over one-quarter 
(27%) reported snorting capsules, stable from 
26% in 2020 (p=0.740). Smaller numbers 
reported shelving/shafting (1%; 3% in 2020; 
p=0.073).  
Quantity: Of those who reported recent use 
and responded (n=542), the median number of 
capsules used in a ‘typical’ session in 2021 
was two (IQR=1-3; 2 capsules in 2020; 
IQR=1.5-3; p<0.001). Of those who reported 
recent use and responded (n=542), the median 
maximum number of capsules used was three 
(IQR=2-4; 4 capsules in 2020; IQR=2-6; 
p<0.001). 
Contents of Capsules: Of those who reported 
recent use and responded (n=531), over three-
quarters (76%) reported that their last capsule 
contained crystal (80% in 2020), whilst 27% 
reported that it contained powder (30% in 
2020). Eight per cent of participants did not 
look at the contents the last time they had used 
capsules (4% in 2020). 
Ecstasy Crystal 
Recent Use (past 6 months):  Recent use of 
crystal was reported by over half the sample 
(53%), stable from 57% reporting recent use in 
2020 (p=0.062) (Table 4). 
Frequency of Use: Of those who had recently 
consumed ecstasy crystal and commented 
(n=408), participants reported consuming 
crystal on a median of 5 days (IQR=2-10) in 
2021, a significant decrease from 6 days in 
2020 (IQR=3-12; p=0.001) (Figure 8). Five per 
cent reported weekly or greater use, a 
significant decline relative to 2020 (12%; 
p<0.001). 
Routes of Administration: Among 
participants who had recently consumed 
ecstasy crystal and commented (n=407), the 
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main route of administration reported was 
swallowing (83%), a significant increase from 
76% in 2020 (p=0.015). This was followed by 
snorting (56%), which significantly decreased 
relative to 2020 (63%; p=0.030). Few 
participants who had recently used crystal 
reported shelving/shafting (3%, 2% in 2020; 
p=0.520). 
Quantity: Of those who reported recent use 
and responded (n=327), the median amount of 
crystal used in a ‘typical’ session was 0.30 
grams (IQR=0.20-0.50; 0.30 grams in 2020; 
IQR=0.20-0.50). Of those who reported recent 
use and responded (n=329), the median 
maximum amount used was 0.40 grams 
(IQR=0.20-0.70; 0.50 grams in 2020; 
IQR=0.30-1.00; p<0.001). 
Ecstasy Powder 
Recent Use (past 6 months): Consistent with 
previous years, powder was the least used 
form of ecstasy in 2021, with 26% of 
participants having recently used this form, a 
significant decline relative to 2020 (35%; 
p<0.001) (Table 5). This decline was most 
prominent in VIC, SA and QLD.  
Frequency of Use: Of those who had recently 
used ecstasy powder and commented (n=204), 
powder was used on a median of 4 days 
(IQR=2-8) in the previous six months, stable 
relative to 2020 (4 days; IQR=2-8; p=0.849) 
(Figure 8). Weekly or more frequent use was 
reported by 6%, stable from 2020 (4%; 
p=0.414). 
Routes of Administration: Among 
participants who had recently used ecstasy 
powder and commented (n=204), snorting was 
the most common route of administration, 
consistent with previous years, though a 
decrease was observed in 2021 (73%; 84% in 
2020; p=0.007). In contrast, 57% reported 
swallowing ecstasy powder, a significant 
increase from 41% in 2020 (p=0.001).   
Quantity: Of those who reported recent use 
and responded (n=144), the median quantity of 
powder used in a ‘typical’ session was 0.30 
grams (IQR=0.20-0.50; 0.30 grams in 2020; 
IQR=0.20-0.50; p=0.619). Of those who 
reported recent use and responded (n=147), 
the median maximum amount used was 0.50 
grams (IQR=0.30-1.00; 0.50 grams in 2020; 
IQR=0.30-1.00; p=0.748).  
Price, Perceived Purity and 
Perceived Availability 
Ecstasy Pills 
Price: The reported price of a pill increased in 
2021, with participants reporting $25 per pill 
(IQR=20-35; n=180; $25 in 2020; IQR=20-30; 
n=400; p<0.001) (Figure 9). 
Perceived Purity: Of those who responded in 
2021 (n=328), the perceived purity of ecstasy 
pills remained stable from 2020 to 2021 
(p=0.078). The largest percentage of 
participants reported perceived purity to be 
‘medium’ (29%; 25% in 2020), with almost 
equal percentages reporting perceived purity 
to be ‘high’ (24%; 31% in 2020), ‘low’ (23%; 
18% in 2020) or ‘fluctuating’ (25%; 25% in 
2020) (Table 6). 
Perceived Availability: Of those who 
responded in 2021 (n=332), the perceived 
availability of ecstasy pills changed 
significantly between 2020 and 2021 
(p=0.013). Over one-third (37%) of participants 
reported ecstasy pills to be ‘easy’ to obtain 
(39% in 2020), with a decrease observed for 
those who reported that pills were ‘very easy’ 
to obtain (24%; 31% in 2020). In contrast, 29% 
reported pills as being ‘difficult’ to obtain (26% 
in 2020) and 10% reported pills as being ‘very 
difficult’ to obtain (5% in 2020) (Table 6).  
Ecstasy Capsules 
Price: The median price of a capsule 
increased significantly in 2021, with 
participants reporting $25 (IQR=20-30; n=291) 
per capsule ($20 in 2020; IQR=15-25; n=570; 
p<0.001) (Figure 9). 
Perceived Purity: Of those who responded in 
2021 (n=531), the perceived purity of capsules 
significantly changed between 2020 and 2021 
(p<0.001). Participants predominantly 
perceived capsules as being of ‘medium’ purity 
(38%; 36% in 2020), with fewer participants 
Ecstasy and Related Drugs Reporting System 2021 
 
  25 
reporting ‘high’ (24%; 35% in 2020) or ‘low’ 
(18%; 11% in 2020) purity (Table 6).  
Perceived Availability: Of those who 
responded in 2021 (n=532), the perceived 
availability of capsules changed significantly 
between 2020 and 2021 (p<0.001). Whilst 
participant reports of capsules being ‘easy’ to 
obtain remained unchanged (47% in 2021 and 
2020, respectively), there was a decrease in 
the per cent of participants perceiving capsules 
to be ‘very easy’ to obtain (28%; 37% in 2020). 
Over one-fifth (22%) perceived capsules to be 
‘difficult’ to obtain, as compared to 15% in 2020 
(Table 6).  
Ecstasy Crystal 
Price: The median price per gram of crystal 
increased from $150 in 2020 (IQR=100-200; 
n=274) to $200 (IQR=150-250; n=209; 
p<0.001) in 2021. Similarly, the median price 
for a point of crystal also increased in 2021 
($25; IQR=20-35; n=27; $20 in 2020; IQR=15-
25; n=76; p=0.007) (Figure 10). 
Perceived Purity: Of those who responded in 
2021 (n=387), the perceived purity of crystal 
significantly changed between 2020 and 2021 
(p<0.001). Specifically, in 2021, fewer 
participants perceived purity to be ‘high’ (31%; 
51% in 2020), whilst more participants 
perceived purity to be ‘medium’ (36%; 27% in 
2020) (Table 6).  
Perceived Availability: Of those who 
responded in 2021 (n=391), the perceived 
availability of crystal changed significantly 
between 2020 and 2021 (p<0.001). Whilst the 
largest percentage of participants perceived 
crystal to be ‘easy’ to obtain in 2021 (43%; 41% 
in 2020), there was an increase in participants 
reporting that it was ‘difficult’ to obtain (27%; 
18% in 2020) (Table 6).  
Ecstasy Powder 
Price: The reported median price per gram of 
powder increased in 2021, from $150 
(IQR=100-200; n=87) in 2020 to $200 
(IQR=150-250; n=69) in 2021 (p<0.001) 
(Figure 10). 
Perceived Purity: Of those who responded in 
2021 (n=144), the perceived purity of powder 
remained stable between 2020 and 2021 
(p=0.296). The largest percentage of 
participants perceived powder to be of 
‘medium’ (34%; 43% in 2020) or ‘high’ (30%; 
30% in 2020) purity in 2021. One-fifth (21%) of 
participants perceived powder to have 
‘fluctuated’ in purity (13% in 2020) (Table 6). 
Perceived Availability: Of those who 
responded in 2021 (n=146), the perceived 
availability of powder remained stable between 
2020 and 2021 (p=0.837). The largest 
percentage (41%) reported that powder was 
‘easy’ to obtain in 2021 (46% in 2020), while 
over one-quarter (27%) reported that it was 
‘very easy’ to obtain (23% in 2020) (Table 6).
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Figure 9: Median price of ecstasy pills and capsules, nationally, 2003-2021 
Note. Among those who commented. Data collection for price of ecstasy capsules started in 2008. The error bars represent the IQR. 
Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; ***p<0.001. 
 
Figure 10: Median price of ecstasy crystal (per gram and point) and powder (per gram only), nationally, 
2013-2021 
 
Note. Among those who commented. Data collection for price of ecstasy crystal (gram and point) and ecstasy powder (gram) started in 
2013. The error bars represent the IQR. Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; ***p<0.001. 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Pill 35 35 35 30 30 30 25 25 30 30 25 25 25 25 25 25 25 25 25





















2013 2014 2015 2016 2017 2018 2019 2020 2021
Crystal (gram) 260 250 250 200 200 200 180 150 200
Powder (gram) 250 250 250 200 200 150 160 150 200
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Table 6: Current perceived purity and availability of different forms of ecstasy, nationally, 2017-2021 
 
 2017 2018 2019 2020 2021 
Current Perceived Purity 
% Pills  (n=566) (n=592) (n=555) (n=417) (n=328) 
Low 17 18 12 18 23 
Medium 37 33 28 25 29 
High 18 23 30 31 24 
Fluctuates 28 26 29 25 25 
% Capsules  (n=563) (n=581) (n=651) (n=612) (n=531) *** 
Low 11 11 7 11 18 
Medium 37 37 33 36 38 
High 34 38 39 35 24 
Fluctuates 18 15 22 18 20 
% Crystal  (n=430) (n=394) (n=444) (n=401) (n=387) *** 
Low 5 5 3 5 12 
Medium 30 32 26 27 36 
High 50 54 62 51 31 
Fluctuates 15 9 10 17 21 
% Powder  (n=122) (n=111) (n=147) (n=128) (n=144) 
Low 14 16 7 14 15 
Medium 51 42 49 43 34 
High 27 33 30 30 30 
Fluctuates 8 8 14 13 21 
Current Perceived Availability 
% Pills  (n=576) (n=597) (n=561) (n=419) (n=332) * 
Very easy 50 43 40 31 24 
Easy 38 40 41 39 37 
Difficult 10 16 16 26 29 
Very difficult 1 2 3 5 10 
% Capsules  (n=567) (n=588) (n=653) (n=610) (n=532) *** 
Very easy 43 38 55 37 28 
Easy 43 47 37 47 47 
Difficult 13 14 8 15 22 
Very difficult 1 1 - 1 4 
% Crystal  (n=433) (n=392) (n=442) (n=406) (n=391) *** 
Very easy 38 30 37 39 23 
Easy 40 44 44 41 43 
Difficult 20 23 18 18 27 
Very difficult 2 4 - 2 6 
% Powder  (n=122) (n=115) (n=148) (n=132) (n=146) 
Very easy 30 20 29 23 27 
Easy 40 48 47 46 41 
Difficult 27 30 22 27 27 
Very difficult 3 2 - 5 5 
Note. The response option ‘Don’t know’ was excluded from analysis. Market questions were only asked for all forms of ecstasy from 2017 
onwards. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021.














Participants were asked about their recent (past six month) use of 
various forms of methamphetamine, including powder (white particles, 
described as ‘speed’), base (wet, oily powder), and crystal (clear, ice-
like crystals).  
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Patterns of Consumption (any methamphetamine) 
Recent Use (past 6 months) 
The per cent reporting any recent use of methamphetamine has been declining since monitoring 
began (Figure 11), whereby 84% of participants reported recent use in 2003. A substantial decline 
ensued in later years, with just over one-quarter (26%) reporting recent use in 2021, stable from 24% 
in 2020 (p=0.374) (Figure 11).   
Frequency of Use  
Use has remained relatively infrequent over the course of monitoring, with participants reporting a 
median of 5 days (IQR=2-24) in 2021 (4 days in 2030; IQR=1-13; p=0.053) (Figure 12). There was, 
however, a significant increase in the per cent of people who had recently used methamphetamine 
who reported use on a weekly or more frequent basis in 2021 (28%) compared to 2020 (17%; 
p=0.022).  
Figure 11: Past six month use of any methamphetamine, and methamphetamine powder, base, and 
crystal, nationally, 2003-2021 
 
Note. – Per cent suppressed due to small cell size (n≤5 but not 0). Significance for 2020 versus 2021 presented in figure; *p<0.050; 





2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Any form 84 83 84 82 71 59 54 56 60 61 50 47 38 38 31 32 33 24 26
Powder 73 68 74 64 57 46 45 47 49 48 37 36 25 25 22 21 21 14 12
Base 36 39 38 34 26 18 15 13 16 15 6 8 3 4 3 4 3 2 1
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Figure 12: Median days of any methamphetamine use, and methamphetamine powder, base, and 
crystal  in the past six months, nationally, 2003-2021 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 20 days to improve visibility of trends. – Per cent suppressed due to small cell size (n≤5 but not 0). 
Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; ***p<0.001.  
 
Patterns of Consumption (by form) 
Methamphetamine Powder 
Recent Use (past 6 months): Powder has 
historically been the most common form used, 
although use has declined substantially since 
2005, dropping to below crystal for the first time 
in 2021 (Figure 11). In 2021, 12% of 
participants had recently consumed powder, 
stable from 2020 (14%; p=0.213). Use 
significantly decreased in the NT sample 
(p=0.004) (Table 8). 
Frequency of Use: Of those who had recently 
consumed powder and commented (n=94), 
median days of use remained stable at 2 days 
in 2021 (IQR=1-5; 3 days in 2020; IQR=1-7; 
p=0.289) (Figure 12). Six per cent reported 
using powder on a weekly or more frequent 
basis in 2021, stable from 9% in 2020 
(p=0.719).  
Routes of Administration: Among 
participants who had recently consumed 
powder and commented (n=93), the main route 
of administration in 2021 was snorting (78%; 
67% in 2020; p=0.084), followed by swallowing 
(30%; 42% in 2020; p=0.102). Smaller 
numbers reported smoking (10%; 10% in 
2020).  
Quantity: Of those who reported recent use 
and responded (n=57), the median amount 
used in a ‘typical’ session was 0.20 grams 
(IQR=0.10-0.50; 0.20 grams in 2020; 
IQR=0.10-0.50; p=0.823). Of those who 
reported recent use and responded (n=59), the 
median maximum amount used was 0.30 
grams (IQR=0.10-0.70; 0.50 grams in 2020; 
IQR=0.20-1.00; p=0.363).  
Methamphetamine Crystal 
Recent Use (past 6 months):  As with all 
forms of methamphetamine, crystal use has 
generally decreased over time (Figure 11). 
Sixteen per cent of the sample had recently 
consumed crystal in 2021 (12% in 2020; 
p=0.061). Recent use of crystal significantly 
increased in the ACT sample (p=0.001) (Table 
9). 
Frequency of Use: Of those who had recently 
consumed crystal and commented (n=119), 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Any form 7 6 4 4 6 4 4 4 4 4 3 4 5 4 5
Powder 6 6 6 6 5 4 3 3 5 3 3 3 2 2 2 2 2 3 2
Base 5 5 5 4 4 4 2 2 4 2 5 5 2 2 2 4 2 5 1
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frequency of use increased significantly in 
2021, from a median of 5 days (IQR=1-24) in 
2020 to a median of 14 days (IQR=4-48) in 
2021 (p=0.007) (Figure 12). Over two-fifths 
(44%) reported using crystal on a weekly or 
more frequent basis in 2021, a significant 
increase from 27% in 2020 (p=0.015). 
Routes of Administration: Smoking 
remained the most common route of 
administration among those who had used 
crystal and commented (n=120), with 93% 
reporting this method in 2021 (85% in 2020; 
p=0.101), followed by injecting (13%; 11% in 
2020; p=0.836) and snorting (8%; 16% in 2020; 
p=0.329). 
Quantity: Of those who reported recent use 
and responded (n=109), the median amount 
used in a ‘typical’ session was 0.20 grams 
(IQR=0.10-0.40; 0.20 grams in 2020; 
IQR=0.10-0.50; p=0.549).  Of those who 
reported recent use and responded (n=108), 
the median maximum amount used was 0.40 
grams (IQR=0.20-0.90; 0.50 grams in 2020; 
IQR=0.20-1.00 gram; p=0.963). 
Table 7: Past six month use of any methamphetamine, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 87 79 98 82 92 91 82 66 
2004 89 77 94 76 90 95 82 70 
2005 83 75 86 78 94 92 76 84 
2006 76 79 91 78 92 88 67 78 
2007 66 60 91 70 90 62 67 58 
2008 66  55  77  63  58  50  24  57  
2009 49  54  72  52  53  44  64  47  
2010 50  70  72  48  57  45  63  51  
2011 49  51  75  52  67  64  91  60  
2012 42  73  84  64  48  47  75  76  
2013 36  65  71  57  46  31  44  48  
2014 32 51 68 64 32 31 47 47 
2015 33  35  55  45  33  20  49  31  
2016 27 26 57 42 36 27 52 39 
2017 30 33 46 40 37 12 35 14 
2018 19 33 60 46 45 11 27 18 
2019 26 33 46 45 34 11 44 24 
2020 17 15 49 31 26 12 24 18 
2021 15 29* 44 31 33 13 14 30 
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Table 8: Past six month use of methamphetamine powder, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 79 64 89 67 65 83 81 57 
2004 81 64 92 68 62 78 72 42 
2005 76 70 85 77 66 85 73 57 
2006 55 66 91 62 51 65 59 58 
2007 45 53 90 65 53 46 55 46 
2008 48 42 75 59 30 38 24 34 
2009 37 44 72 46 30 37 61 41 
2010 29 66 70 40 38 38 59 47 
2011 32 50 69 47 45 44 91 49 
2012 31 63 77 61 24 27 58 58 
2013 25 57 58 53 21 17 34 41 
2014 21 48 56 58 13 19 39 34 
2015 27 31 45 39 11 6 31 11 
2016 18 21 50 32 12 18 27 25 
2017 18 32 43 29 19 7 20 9 
2018 14 25 56 30 15 - 14 10 
2019 17 23 41 33 16 - 28 9 
2020 8 12 39 25 6 - 14 8 
2021 8 9 36 20 - - -** 15 
Note. – Per cent suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Table 9: Past six month use of methamphetamine crystal, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 48 56 64 52 48 77 40 38 
2004 46 39 52 16 47 80 35 42 
2005 40 26 42 10 41 69 32 50 
2006 56 37 49 27 62 77 26 50 
2007 42 20 39 7 49 52 24 23 
2008 33 24 22 15 34 36 0 26 
2009 9 8 13 7 32 20 15 17 
2010 21 16 18 - 26 22 22 8 
2011 19 9 38 - 43 46 - 32 
2012 18 26 48 10 32 33 - 40 
2013 11 14 45 17 28 22 21 21 
2014 13 8 34 14 20 17 27 26 
2015 12 7 19 13 26 16 36 20 
2016 15 5 18 21 33 12 32 18 
2017 12 8 10 14 26 6 24 7 
2018 6 15 14 24 40 8 21 12 
2019 13 15 12 20 26 8 31 16 
2020 10 4 14 12 21 10 12 14 
2021 - 21** 13 15 32 10 12 16 
Note. - Per cent suppressed due to low numbers (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
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Price, Perceived Purity and 
Perceived Availability 
Methamphetamine Powder 
Price: Participants reported a median price of 
$200 per gram (IQR=165-200, n=24; $200 in 
2020; IQR=150-250; n=31; p=0.756) and $50 
for one point in 2021 (IQR=40-63; n=7; $50 in 
2020; IQR=30-60; n=17; p=0.846) (Figure 13). 
Perceived Purity: Of those who responded in 
2021 (n=61), perceived purity of powder 
remained stable between 2020 and 2021 
(p=0.787). There were similar percentages 
who perceived purity as being ‘high’ (38%; 41% 
in 2020) and ‘medium’ (34%; 38% in 2020) 
(Figure 15).  
Perceived Availability: Of those who 
responded in 2021 (n=66), perceived 
availability of powder remained stable between 
2020 and 2021 (p=0.530). Almost one-third 
(32%) reported that powder was ‘very easy’ 
(28% in 2020) or ‘easy’ (27%; 38% in 2020) to 
obtain, respectively. Over one-tenth (12%) 
perceived powder as being ‘very difficult’ to 
obtain (7% in 2020) and 29% perceived it as 
being ‘difficult’ to obtain (28% in 2020) (Figure 
17).  
Methamphetamine Crystal 
Price: Participants reported a median price of 
$425 per gram (IQR=250-500; n=16; $300 in 
2020; IQR=250-320; n=21; p=0.052) and $60 
per point (IQR=50-100; n=44; $50 in 2020; 
IQR=48-80, n=56; p=0.100) (Figure 14). 
Perceived Purity: Of those who responded in 
2021 (n=107), perceived purity of crystal 
remained stable between 2020 and 2021 
(p=0.788).  The largest per cent (46%) reported 
purity as ‘high’, unchanged from 2020 (46%). 
‘Medium’ and ‘low’ purity was reported by 23% 
and 12%, respectively (Figure 16).  
Perceived Availability: Of those who 
responded in 2021 (n=114), perceived 
availability of crystal remained stable between 
2020 and 2021 (p=0.159). Over two-fifths 
(44%) of participants regarded crystal as ‘very 
easy’ to obtain in 2021, consistent with reports 
in 2020 (44%) (Figure 18). Sixteen per cent 
commented that crystal was ‘difficult’ to obtain 
(21% in 2020).
Figure 13: Median price of powder methamphetamine per point and gram, nationally, 2003-2021 
 
Note. Among those who commented. The error bars represent the IQR. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Point 40 40 50 30 40 40 50 50 25 50 30 50 50 50 33 45 50 50 50



















Ecstasy and Related Drugs Reporting System 2021 
 
  34 
Figure 14: Median price of crystal methamphetamine per point and gram, nationally, 2003-2021 
 
Note. Among those who commented. The error bars represent the IQR. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Point 50 40 50 50 50 50 50 50 90 100 100 100 100 75 50 50 50 50 60
























Figure 15: Current perceived purity of powder methamphetamine, nationally, 2003-2021 
 













































Fluctuates 14 14 16 11 14 13 9 16 10 13 7 12 6 4 4 5 19 5 10
High 29 23 24 27 26 18 18 23 35 35 37 30 25 34 45 39 38 41 38
Medium 37 36 34 32 33 33 48 48 39 35 36 40 48 42 32 43 32 38 34





























Figure 16: Current perceived purity of crystal methamphetamine, nationally, 2003-2021 
 













































Fluctuates 6 6 8 10 10 7 5 12 15 13 16 15 15 13 12 17 22 18 19
High 71 57 51 49 51 40 39 50 60 62 46 49 46 50 45 55 55 46 46
Medium 19 25 24 25 24 31 27 23 21 22 32 29 34 35 25 25 19 19 23





























Figure 17: Current perceived availability of powder methamphetamine, nationally, 2003-2021 
 













































Very difficult 1 2 2 2 1 3 1 2 1 3 4 4 7 12 5 11 9 7 12
Difficult 9 14 14 19 16 24 21 18 12 21 19 23 34 28 30 24 22 28 29
Easy 46 39 39 39 49 46 21 52 42 44 41 42 34 42 39 47 41 38 27





























Figure 18: Current perceived availability of crystal methamphetamine, nationally, 2003-2021 
 








































Very difficult 3 5 7 6 4 5 4 0 0 1 1 3 2 0 0 0 1 8 3
Difficult 11 21 30 21 18 20 30 21 14 10 11 12 2 8 10 6 5 21 16
Easy 23 31 39 36 30 34 36 36 46 42 32 34 30 29 34 28 30 27 38








































Participants were asked about their recent (past six month) use of 
various forms of cocaine, including powder and ‘crack’ cocaine. 
Cocaine hydrochloride, a salt derived from the coca plant, is the most 
common form of cocaine available in Australia. ‘Crack’ cocaine is a 
form of freebase cocaine (hydrochloride removed), which is particularly 
pure. ‘Crack’ is most prevalent in North America and infrequently 
encountered in Australia. 
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Patterns of Consumption 
Recent Use (past 6 months) 
Recent cocaine use has gradually increased over the years. The per cent reporting any recent use 
increased from 68% in 2020 to 80% in 2021 (p<0.001), the largest per cent observed since monitoring 
commenced (Figure 19). At the jurisdiction level, significant increases in use were observed in TAS 
(61% in 2020 versus 84% in 2021; p<0.001), NSW (84% in 2020 versus 94% in 2021; p=0.034) and 
VIC (76% in 2020 versus 90% in 2021; p=0.014) (Table 10).  
Frequency of Use  
Of those who had recently consumed cocaine and commented in 2021 (n=619), the median days of 
use amongst consumers was 5 (IQR=2-10; 4 days in 2020; IQR=2-10; p=0.123) (Figure 19). This is 
equivalent to less than monthly use. Seven per cent reported using cocaine weekly or more frequently 
(7% in 2020; p=0.659). 
Routes of Administration 
Among participants who had recently consumed cocaine and commented (n=621), the main route of 
administration was snorting (98%; 99% in 2020; p=0.350) followed by swallowing (9%; 7% in 2020; 
p=0.349). 
Quantity 
Among those who reported recent use and responded (n=410), the median amount used in a ‘typical’ 
session was 0.50 grams (IQR=0.30-1.00; 0.50 grams in 2020; IQR=0.30-1.00; p=0.032). Of those 
who reported recent use and responded (n=428), the median maximum amount used was 1.00 gram 
(IQR=0.50–1.10; 1.00 gram in 2020; IQR=0.50-1.50; p=0.302).  
 
Figure 19: Past six month use and frequency of use of cocaine, nationally, 2003-2021 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 10 days to improve visibility of trends. Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; 
***p<0.001. 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Used 23 27 41 37 40 36 39 48 46 40 36 44 42 47 48 59 67 68 80
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Table 10: Past six month use of cocaine, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 46 26 35 7 37 17 - 18 
2004 46 34 48 10 26 16 16 21 
2005 55 44 63 20 49 35 11 41 
2006 45 44 55 33 31 29 - 36 
2007 62 46 54 35 36 27 - 41 
2008 51 45 51 35 20 40 - 30 
2009 64 44 48 31 20 24 23 55 
2010 59 58 54 49 42 26 52 51 
2011 59 43 43 39 45 32 - 52 
2012 57 37 54 26 37 31 - 34 
2013 42 38 46 17 35 34 34 40 
2014 67 51 58 22 45 30 39 42 
2015 61 41 46 17 45 29 52 39 
2016 70 44 56 24 57 38 42 41 
2017 62 48 53 24 60 31 57 50 
2018 71 75 84 42 55 47 40 60 
2019 83 75 80 38 71 47 74 67 
2020 84 89 76 61 69 48 59 61 
2021 94* 91 90* 84*** 78 59 71 73 
Note. - Per cent suppressed due to low numbers (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
Price, Perceived Purity and Perceived Availability 
Price 
The median price per gram of cocaine significantly increased in 2021, from $300 (IQR=300-350; 
n=348) in 2020 to $350 (IQR=300-350; n=310) in 2021 (p<0.001) (Figure 20). 
Perceived Purity 
Among those able to comment in 2021 (n=488), perceived purity significantly changed between 2020 
and 2021 (p=0.005). Specifically, almost one-fifth (18%) perceived purity to be ‘high’, a decrease from 
28% in 2020, and one-third (33%) perceived purity to be ‘medium’, as compared to 30% in 2020 
(Figure 21).  
Perceived Availability 
Among those able to comment in 2021 (n=482), perceived availability had significantly changed 
between 2020 and 2021 (p=0.004). Whilst over two-fifths (44%) reported that cocaine was ‘easy’ to 
obtain, unchanged from 2020 (44%), there was an increase in the per cent of participants who 
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Figure 20: Median price of cocaine per gram, nationally, 2003-2021 
  
Note. Among those who commented. The error bars represent the IQR. Significance for 2020 versus 2021 presented in figure; *p<0.050; 
**p<0.010; ***p<0.001.
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
























Figure 21: Current perceived purity of cocaine, nationally, 2003-2021 
 













































Fluctuates 10 12 5 8 7 9 9 14 9 8 5 14 10 13 8 13 15 17 20
High 17 21 29 21 24 13 29 22 15 26 26 23 23 16 24 25 24 28 18
Medium 37 26 30 33 34 38 28 42 38 35 44 37 34 39 38 35 33 30 33





























Figure 22: Current perceived availability of cocaine, nationally, 2003-2021 
  








































Very difficult 18 12 12 11 7 10 7 6 7 8 7 6 7 8 12 4 3 5 3
Difficult 33 40 41 41 36 37 35 34 44 44 35 37 32 37 34 34 27 28 21
Easy 13 28 31 28 34 32 42 39 32 33 41 40 42 41 38 42 44 44 44


































Participants were asked about their recent (past six month) use 
of indoor-cultivated cannabis via a hydroponic system 
(‘hydroponic’) and outdoor-cultivated cannabis (‘bush’), as well 
as hashish and hash oil.  




Recent Use (past 6 months) 
At least four in five participants have reported 
any recent use of cannabis each year since 
2009. In 2021, 84% of participants reported 
any recent use, which was a significant 
decrease from 88% in 2020 (p=0.024) (Figure 
23). There were, however, no significant 
changes in recent use across any of the 
jurisdictions from 2020 to 2021 (Table 11). 
Frequency of Use  
Typical frequency of use has varied between 
weekly and several times a week over the 
course of monitoring. Of those who had 
recently consumed cannabis and commented 
(n=416), participants reported a median of 48 
days of use (IQR=10-170) in 2021, stable 
relative to 2020 (48 days; IQR=10-150; 
p=0.458) (Figure 23). Sixty-four per cent 
reported using cannabis weekly or more 
frequently (62% in 2020; p=0.412), including 
almost one-quarter (24%; n=156) who reported 
using cannabis daily (21% in 2020; p=0.139).   
Routes of Administration 
Among participants who had recently 
consumed cannabis and commented (n=648), 
nearly all reported smoking cannabis (95%; 
95% in 2020; p=0.916), consistent across all 
years. Over one-third (34%) reported 
swallowing (35% in 2020; p=0.779) and almost 
one-quarter (24%) reported inhaling/vaporising 
cannabis (26% in 2020; p=0.557).  
Quantity 
Of those who reported recent use, the median 
‘typical’ amount used on the last occasion of 
use was 1.00 gram (IQR=0.50-2.00; n=195; 
1.00 gram in 2020; IQR=1.00-2.00; p=0.054), 
two cones (IQR=1-4; n=187; 3 cones in 2020; 
IQR=1.5-5; p=0.030) or one joint (IQR=0.5-1.5; 
n=220; 1 joint in 2020; IQR=1-2; p=0.191).  
Forms Used 
Among all EDRS participants, the majority 
reported recent use of hydroponic cannabis 
(71%; 74% in 2020; p=0.327) and two-thirds 
(67%) also reported recent use of outdoor-
grown ‘bush’ cannabis (71% in 2020; p=0.199). 
Fewer participants reported having used 
hashish (11%; 17% in 2020; p=0.007) and 
hash oil (11%; 14% in 2020; p=0.082) in the 
preceding six months. One-tenth (10%) of 
participants reported recent use of (non-
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Figure 23: Past six month use and frequency of use of cannabis, nationally, 2003-2021 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; ***p<0.001.    
 
Table 11: Past six month use of cannabis (any form), by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 82 82 82 90 88 91 95 73 
2004 85 83 78 91 81 84 87 70 
2005 82 81 88 89 87 83 79 83 
2006 73 83 79 82 83 85 84 92 
2007 74 85 82 68 80 80 96 87 
2008 71 86 84 74 74 85 40 81 
2009 83 89 85 76 86 85 60 84 
2010 78 89 89 72 84 81 70 72 
2011 83 89 86 67 92 86 73 93 
2012 86 92 85 69 88 77 83 81 
2013 90 87 87 78 85 92 73 84 
2014 85 74 81 76 87 86 84 87 
2015 91 82 90 80 92 86 82 93 
2016 85 85 86 77 97 87 82 86 
2017 93 95 88 84 89 82 88 93 
2018 91 88 84 94 85 86 93 95 
2019 81 81 86 88 82 86 83 92 
2020 91 85 89 84 90 87 91 90 
2021 88 86 84 75 84 82 83 89 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021.  
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Used 85 81 84 83 81 76 82 80 85 82 85 83 87 86 89 90 85 88 84









































Ecstasy and Related Drugs Reporting System 2021 
 
 48 
Price, Perceived Potency and 
Perceived Availability 
Hydroponic Cannabis 
Price: The median price per gram of 
hydroponic cannabis nationally has 
consistently been $20 (IQR=17-28; n=39; $20 
in 2020; IQR=15-30; n=89; p=0.443). The 
median price paid per ounce of hydroponic 
cannabis nationally was $330 (IQR=250-400; 
n=86; $300 in 2020; IQR=270-350; n=109; 
p=0.117) (Figure 24A).  
Perceived Potency: Of those able to comment 
in 2021 (n=322), perceived potency of 
hydroponic cannabis significantly changed 
between 2020 and 2021 (p=0.001). The 
majority (62%) of participants reported potency 
to be ‘high’, an increase from 48% in 2020, and 
almost one-quarter (23%) reported potency to 
be ‘medium’, a slight decrease from 27% in 
2020 (Figure 25A).  
Perceived Availability: Of those able to 
comment in 2021 (n=327), perceived 
availability of hydroponic cannabis remained 
stable between 2020 and 2021 (p=0.120). The 
majority of participants reported hydroponic 
cannabis to be ‘very easy’ to obtain (56%; 48% 
in 2020) and one-third (33%) reported 
hydroponic to be ‘easy’ to obtain (41% in 2020) 
(Figure 26A).  
Bush Cannabis 
Price: The median price per gram for bush 
cannabis was $20 (IQR=15-28; n=27) in 2021, 
stable relative to 2020 ($20; IQR=15-25; n=73; 
p=0.482). The median price for an ounce also 
remained stable, with participants in 2021 
reporting a median of $250 (IQR=200-320; 
n=69; $300 in 2020; IQR=240-320; n=91; 
p=0.302) (Figure 24B).  
Perceived Potency: Among those that were 
able to comment in 2021 (n=278), perceived 
potency of bush cannabis significantly 
changed between 2020 and 2021 (p=0.001). 
Almost half (49%) reported potency to be 
‘medium’, an increase from 37% in 2020. 
Fewer participants (13%) reported potency to 
be ‘low’ in 2021, compared to 18% in 2020 
(Figure 25B).  
Perceived Availability: Of those able to 
comment in 2021 (n=276), perceived 
availability of bush cannabis significantly 
changed between 2020 and 2021 (p=0.023). 
Those reporting bush cannabis as ‘difficult’ 
(16% respectively) or ‘very difficult’ (5%; 3% in 
2020) to obtain remained largely unchanged 
between 2020 and 2021. There was, however, 
an increase in participants reporting bush 
cannabis to be ‘very easy’ to obtain (53%; 40% 
in 2020) and an inverse decrease in those 
reporting that it was ‘easy’ to obtain (26%; 41% 
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Figure 24: Median price of hydroponic (A) and bush (B) cannabis per ounce and gram, nationally, 
2006-2021 
 
(A) Hydroponic cannabis 
 
(B) Bush cannabis 
 
Note. From 2006 onwards hydroponic and bush cannabis data collected separately. The error bars represent the IQR. *p<0.050; **p<0.010; 
***p<0.001 for 2020 versus 2021.
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Gram 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20




















2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Gram 20 13.5 20 20 20 20 20 15 20 20 20 18 20 20 20 20






















Figure 25: Current potency of hydroponic (A) and bush (B) cannabis, nationally, 2006-2021 
 





































Fluctuates 10 8 16 8 14 10 11 12 13 13 11 15 13 9 17 11
High 59 64 49 59 58 60 56 50 51 39 47 52 50 50 48 62
Medium 22 23 32 30 26 28 31 34 31 36 39 27 31 33 27 23





























(B) Bush cannabis 
 





































Fluctuates 9 3 9 10 13 10 8 5 11 7 8 5 8 8 12 8
High 19 27 21 22 14 21 20 27 21 21 19 18 25 31 33 30
Medium 49 50 51 55 48 54 55 52 49 52 50 52 44 40 37 49





























Figure 26: Current perceived availability of hydroponic (A) and bush (B) cannabis, nationally, 2006-2021 
 





































Very difficult 1 4 1 2 1 0 0 1 1 0 1 1 2 0 0 1
Difficult 7 19 16 16 13 7 5 9 7 9 7 5 15 9 10 9
Easy 27 30 36 34 37 29 29 30 35 25 26 24 36 25 41 33






























(B) Bush cannabis 
 
Note. The response ‘Don’t know’ was excluded from analysis. From 2006 onwards hydroponic and bush cannabis data collected separately. – Per cent suppressed due to small cell size (n≤5 but not 


































Very difficult 3 6 4 3 2 3 5 1 4 1 1 4 4 4 3 5
Difficult 16 25 23 28 26 20 16 18 17 20 18 21 20 18 16 16
Easy 35 33 35 34 35 39 42 35 38 33 30 31 38 33 41 26































Ketamine, LSD and DMT 
Participants were asked about their recent (last six month) use of 
various forms of ketamine, lysergic acid diethylamide (LSD) and N,N-
Dimethyltryptamine (DMT).  
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Ketamine 
Patterns of Consumption 
Recent Use (past 6 months): The per cent of the sample reporting any recent use of ketamine 
declined from the beginning of monitoring to 2009, with an increase observed from then onwards. In 
2021, 52% of participants reported recent use, a significant increase from 43% in 2020 (p<0.001) 
(Figure 27), and the largest per cent reporting recent use since the commencement of monitoring. In 
2021, jurisdictional estimates ranged from over one-quarter (28%) of the SA sample reporting recent 
use to over four-fifths (81%) of the VIC sample. The per cent reporting recent use increased 
significantly from 2020 to 2021 in the NSW (p=0.002) and the NT (p<0.001) samples (Table 12). 
Frequency of Use: Of those who had recently consumed ketamine and commented (n=404), 
frequency of use remained stable in 2021 compared to 2020 (median 3 days; IQR=2-8; 3 days in 
2020; IQR=2-8; p=0.748) (Figure 27). The per cent that reported weekly or more frequent use also 
remained stable at 7% (4% in 2020; p=0.213). 
Routes of Administration: Among participants who had recently consumed ketamine and 
commented (n=404), the most common route of administration was snorting (96%; 97% in 2020; 
p=0.701) followed by swallowing (5%; 6% in 2020; p=0.511). Smaller percentages (n≤5) reported 
smoking, injecting and shelving/shafting; therefore, numbers are suppressed.  
Quantity: Among those who reported recent use and responded (n=237), the median amount used 
in a ‘typical’ session was 0.30 grams (IQR=0.20-0.50; 0.30 grams in 2020; IQR=0.20-0.50; n=180; 
p=0.893). Of those who reported recent use and responded (n=248), the median maximum quantity 
used was 0.50 grams (IQR=0.30-1.00; 0.50 grams in 2020; IQR=0.30-0.70; n=188; p=0.418). 




Figure 27: Past six month use and frequency of use of ketamine, nationally, 2003-2021 
 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 10 days to improve visibility of trends. 
Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; ***p<0.001.    
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Used 26 23 21 14 16 12 10 12 16 14 19 18 15 26 37 35 41 43 52
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Table 12: Past six month use of ketamine, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 49 21 51 24 36 12 7 14 
2004 39 15 45 - 39 10 18 16 
2005 39 17 35 11 24 11 7 20 
2006 27 15 29 6 11 - - 12 
2007 36 10 25 14 26 - - - 
2008 30 6 20 6 20 - 0 - 
2009 19 - 21 - 19 6 0 6 
2010 24 6 23 6 13 - - 8 
2011 39 14 26 8 8 0 0 - 
2012 24 14 35 - 10 - - 7 
2013 24 33 46 9 6 7 - 13 
2014 23 6 63 14 - 11 15 - 
2015 24 9 50 - - - 18 - 
2016 50 20 72 - 15 18 11 22 
2017 50 49 80 17 48 16 11 21 
2018 54 29 90 23 24 22 11 28 
2019 68 33 84 17 33 25 39 27 
2020 53 47 78 52 32 31 24 28 
2021 76** 51 81 46 28 41 55*** 37 
Note. – Data not published due to small numbers commenting (n≤5). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Price, Perceived Purity and Perceived Availability 
Price: Historically, the median reported price of ketamine per gram decreased from $200 in 2003 to 
$135 in 2006, returning to the same median price from 2014-2020. In 2021, there was a significant 
increase in price, with participants reporting a median of $220 per gram (IQR=200-250; n=157; $200 
in 2020; IQR=170-250; n=169; p<0.001) (Figure 28). 
Perceived Purity: Among those able to comment in 2021 (n=267), perceived purity of ketamine 
remained stable between 2020 and 2021 (p=0.541). Over half (55%) perceived purity as being ‘high’ 
(60% in 2020), followed by one-quarter (25%) reporting ‘medium’ perceived purity in 2021 (25% in 
2020) (Figure 29).  
Perceived Availability: Of those able to comment in 2021 (n=276), perceived availability of ketamine 
significantly changed between 2020 and 2021 (p=0.030). Over one-third (34%) perceived ketamine 
to be ‘easy’ to obtain, a decrease from 40% in 2020, and 24% perceived it to be ‘very easy’ to obtain 
(17% in 2020). A decrease was also observed in the percentage of participants who reported 
ketamine as being ‘difficult’ to obtain, from 37% in 2020 to 31% in 2021 (Figure 30).  
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Figure 28: Median price of ketamine per gram, nationally, 2003-2021 
 
Note. Among those who commented. The error bars represent the IQR. Significance for 2020 versus 2021 presented in figure; *p<0.050; 
**p<0.010; ***p<0.001.    
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021


























Figure 29: Current perceived purity of ketamine, nationally, 2003-2021 
 
 













































Fluctuates 8 5 5 6 3 5 8 4 4 0 7 6 11 20 10 9 11 10 12
High 55 54 54 47 59 54 42 52 63 60 61 58 65 54 58 54 61 60 55
Medium 21 23 27 31 14 21 35 26 26 35 15 29 13 21 29 30 26 25 25





























Figure 30: Current perceived availability of ketamine, nationally, 2003-2021 
 
  










































Very difficult 4 10 12 8 19 18 15 30 11 11 4 17 13 4 6 9 15 6 11
Difficult 23 37 36 39 32 20 42 37 38 45 30 35 40 33 30 26 32 37 31
Easy 23 36 38 37 26 29 31 20 26 40 37 36 26 38 42 44 31 40 34





























Patterns of Consumption 
Recent Use (past 6 months): The per cent reporting any recent use of LSD has been gradually 
increasing over the course of monitoring. In 2021, the largest per cent of participants reporting recent 
use was observed since the commencement of monitoring, with 53% of participants reporting use in 
the previous six months, stable from 49% in 2020 (p=0.099) (Figure 31). Variation in use was 
observed across jurisdictions in 2021, ranging from 35% in the SA sample to 63% in the TAS sample 
(Table 13). A significant decrease was observed in the SA sample, from 52% in 2020 to 35% in 2021 
(p=0.027), whilst a significant increase was observed in the NT sample, from 42% in 2020 to 59% in 
2021 (p=0.024).  
Frequency of Use: Of those who had recently consumed LSD and commented (n=412), use was 
reported as infrequent and stable, with a median of 3 (IQR=1-6) days of use in 2021 (3 days in 2020; 
IQR=1-5; p=0.278) (Figure 31). In addition, 4% reported using LSD on a weekly or more frequent 
basis (3% in 2020; p=0.506).  
Routes of Administration: Among participants who had recently consumed LSD and commented 
(n=411), the most common route of administration was swallowing (100%; 99% in 2020; p=0.585).  
Quantity: Among those who reported recent use and responded (n=269), the median amount used 
in a ‘typical’ session was one tab (IQR=0.50-1.00; 1 tab in 2020; IQR=0.50-1.50; n=225; p=0.047). Of 
those who reported recent use and responded (n=268), the median maximum amount used was one 









Figure 31: Past six month use and frequency of use of LSD, nationally, 2003-2021 
 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 10 days to improve visibility of trends. 
*p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Used 28 26 32 29 28 30 34 38 46 34 43 41 40 45 50 51 47 49 53
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Table 13: Past six month use of LSD, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 27 44 48 24 30 22 25 18 
2004 20 23 40 32 36 11 31 18 
2005 33 30 38 31 48 35 15 23 
2006 17 18 37 29 34 25 41 38 
2007 22 24 39 20 33 23 33 28 
2008 18 37 29 41 35 21 16 32 
2009 37 35 46 34 37 31 11 30 
2010 44 41 49 27 35 35 26 38 
2011 46 39 57 43 30 36 60 52 
2012 43 38 38 30 19 33 - 34 
2013 51 53 52 38 25 41 40 41 
2014 43 19 49 35 35 45 43 57 
2015 60 37 46 41 37 24 32 41 
2016 65 40 52 39 30 50 32 55 
2017 73 64 52 39 36 33 47 52 
2018 71 43 64 41 36 39 52 61 
2019 48 42 55 44 43 43 52 53 
2020 44 41 61 60 52 43 42 49 
2021 57 45 53 63 35* 55 59* 60 
Note. – Data not published due to small numbers commenting (n<5). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Price, Perceived Purity and Perceived Availability 
Price: In 2021, participants reported a median of $25 per tab (IQR=20-25; n=189; $20 in 2020; 
IQR=15-25; n=302; p=0.173) (Figure 32). 
Perceived Purity: Of those who commented in 2021 (n=355), perceived purity of LSD remained 
stable between 2020 and 2021 (p=0.200). Specifically, over three-fifths (61%) reported purity as ‘high’ 
(58% in 2020) and one-quarter (26%) reported it as ‘medium’ (23% in 2020) (Figure 33).  
Perceived Availability: Of those able to comment in 2021 (n=364), perceived availability of LSD 
significantly changed between 2020 and 2021 (p=0.034). Forty-four per cent perceived LSD to be 
‘easy’ to obtain, unchanged from 43% in 2020, whilst one-quarter (25%) reported LSD to be ‘very 
easy’ to obtain, an increase from 18% in 2020 (Figure 34). Inversely, there was a slight decrease in 
the percentage of participants who reported LSD as being ‘difficult’ to obtain (27%; 33% in 2020).  
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Figure 32: Median price of LSD per tab, nationally, 2003-2021 
Note. Among those who commented. The error bars represent the IQR. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021.
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021





















Figure 33: Current perceived purity of LSD, nationally, 2003-2021 
  













































Fluctuates 9 8 6 11 8 10 8 10 12 8 10 12 11 15 15 9 16 12 10
High 17 28 44 41 45 44 60 55 52 53 40 55 54 48 54 57 58 58 61
Medium 32 32 24 30 24 28 25 32 31 34 40 30 29 33 28 30 25 23 26





























Figure 34: Current perceived availability of LSD, nationally, 2003-2021 
 









































Very difficult 19 13 7 6 11 3 6 3 3 3 5 5 6 6 6 6 5 7 4
Difficult 29 40 37 33 36 29 33 28 25 35 28 29 38 25 33 33 38 33 27
Easy 12 28 35 37 29 40 38 45 43 40 40 40 37 39 39 42 39 43 44





























Patterns of Consumption 
Recent Use (past 6 months): The per cent reporting DMT use has fluctuated over the reporting 
period, however, has consistently remained below 20% of the sample. In 2021, almost one-fifth (18%) 
of participants reported recent use, a significant increase from 13% in 2020 (p=0.015) (Figure 35).  
Frequency of Use: Use across the years has shown to be infrequent and stable, with a median of 2 
(IQR=1-3) days of use in 2021 (2 days in 2020; IQR=1-3; p=0.680) (Figure 35).  
Routes of Administration: Among participants who had recently consumed DMT and commented 
(n=136), the most common route of administration was smoking (98%; 97% in 2020). Smaller 
percentages (n≤5) reported injecting, swallowing and shelving/shafting; therefore, numbers are 
suppressed. No participants reported snorting DMT in 2021. 
Quantity: Among those who reported recent use and responded (n=41), the median amount used in 
a ‘typical’ session was 25 mgs (IQR=2-100; 27.5 mgs in 2020; IQR=10-67.5; p=0.844). Of those who 
reported recent use and responded (n=41), the median maximum amount used was 40 mgs (IQR=3-
100; maximum quantity of DMT not asked in 2020).  
 
Figure 35: Past six month use and frequency of use of DMT, nationally, 2010-2021 
 
 
Note. Data collection for DMT started in 2010. Median days computed among those who reported recent use (maximum 180 days). Median 
days rounded to the nearest whole number. Y axis reduced to 10 days to improve visibility of trends. Significance for 2020 versus 2021 
presented in figure; *p<0.050; **p<0.010; ***p<0.001.     
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Used 7 13 13 14 14 11 15 18 18 15 13 18
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Table 14: Past six month use of DMT, by jurisdiction, 2010-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2010 7 - 15 7 - 8 0 - 
2011 8 18 29 - 8 25 - 6 
2012 15 14 14 6 - 22 - 15 
2013 9 8 25 11 14 22 - 14 
2014 11 7 30 9 10 19 8 18 
2015 10 6 25 - 11 13 6 9 
2016 15 12 23 - 10 18 16 23 
2017 20 21 23 - 22 23 13 18 
2018 17 16 29 9 23 17 12 16 
2019 17 13 16 6 16 22 17 16 
2020 18 7 10 13 13 20 7 16 
2021 14 18* 16 16 13 27 13 26 
Note. – Data not published due to small numbers commenting (n≤5). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Price, Perceived Purity and Perceived Availability 
Data on the price, perceived purity and perceived availability for DMT were not collected. 










New psychoactive substances (NPS) are often defined as 
substances which do not fall under international drug control, 
but which may pose a public health threat. However, there is 
no universally accepted definition, and in practicality the term 
has come to include drugs which have previously not been well-
established in recreational drug markets. Participants were 
asked about their recent (past six month) use of various NPS. 
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New Psychoactive Substances (NPS) 
In previous (2010-2020) EDRS reports, DMT and paramethoxyamphetamine (PMA) were categorised 
as NPS. However, the classification of these substances as NPS is not universally accepted, and the 
decision was made to exclude them from this category from hereon-in. This means that the figures 
presented below for recent use of tryptamine, phenethylamine and any NPS will not align with those 
in our previous reports.  
Further, some organisations (e.g., the United Nations Office on Drugs and Crime) include plant-based 
substances in their definition of NPS, whilst other organisations exclude them. To allow comparability 
with both methods, we present figures for ‘any’ NPS use, both including and excluding plant-based 
NPS.  
Patterns of Consumption 
Recent Use (past 6 months) 
Any NPS use, including plant-based NPS, has fluctuated over time, peaking at 44% in 2013 and 
declining to 16% in 2021 (15% in 2020; p=0.742) (Table 15). Any NPS use, excluding plant-based 
NPS, has shown a similar trend, peaking at 42% in 2013 and declining to 14% in 2021 (12% in 2020; 
p=0.453) (Table 16). Similar trends have been observed across all jurisdictions. In 2021, any NPS 
use (both including and excluding plant-based NPS) was highest in the VIC sample (23% and 21%, 
respectively) and lowest in the SA (10% and 8%, respectively) and WA samples (10% and 9%, 
respectively) (Table 15). 
Forms Used 
Participants are asked about a range of NPS each year, updated to reflect key emerging substances 
of interest. Whilst the 2C class and synthetic cannabinoids have been highly endorsed over the course 
of monitoring, both peaking in 2013 (20% and 16%, respectively), the per cent reporting recent use 
of both substances has declined in recent years, with 6% reporting recent use of any 2C substance 
in 2021 (5% in 2020; p=0.826), and 2% reporting recent use of synthetic cannabinoids in 2021, a 
significant decline relative to 2020 (4%; p=0.019). Similarly, use of mephedrone (the most commonly 
reported NPS in 2010) has decreased over recent years (less than five participants reported recent 
mephedrone use in 2021, therefore numbers are suppressed).  
Two per cent of the national sample reported recent use of new drugs that mimic the effects of 
psychedelic drugs like LSD in 2021 (1% in 2020; p=0.158). Two per cent of the national sample also 
reported recent use of benzodiazepine NPS in 2021 (1% in 2020; p=0.108), with one per cent 
reporting recent use of etizolam (n≤5 participants reported recent use of etizolam in 2020; p=0.071). 
Less than five participants reported recent use of new drugs that mimic the effects of ecstasy or new 
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Table 15: Past six month use of any NPS (including plant-based NPS), nationally and by jurisdiction, 
2010-2021 
 
% National NSW ACT VIC TAS SA WA NT QLD 
2010 24 10 15 29 49 23 32 - 16 
2011 36 35 36 40 33 49 54 - 22 
2012 40 42 53 45 26 43 29 - 48 
2013 44 52 48 45 34 38 45 38 47 
2014 35 34 17 34 38 38 39 25 56 
2015 37 40 33 36 22 49 32 39 39 
2016 28 38 27 31 14 28 21 25 41 
2017 26 32 25 29 17 31 22 26 26 
2018 23 26 20 28 23 29 13 17 27 
2019 20 16 28 17 18 27 8 19 27 
2020 15 23 13 12 10 17 9 13 21 
2021 16 17 18 23 11 10 10 20 15 
Note. Monitoring of NPS first commenced in 2010. DMT and PMA have been removed as NPS in this year’s report (i.e., 2010-2021 figures 
exclude DMT and PMA; refer to Chapter 8 for further information on DMT use among the sample). This has had a substantial impact on 
the percentage of the sample reporting ‘any’ NPS use in the past six months and means that the figures presented above will not align with 
those presented in previous EDRS reports. – Per cent suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 
for 2020 versus 2021.  
 
Table 16: Past six month use of any NPS (excluding plant-based NPS), nationally and by jurisdiction, 
2010-2021 
 
% National NSW ACT VIC TAS SA WA NT QLD 
2010 24 9 15 28 48 22 31 - 15 
2011 33 31 26 37 33 47 50 - 21 
2012 37 42 49 40 24 37 27 - 48 
2013 42 52 44 45 33 36 43 36 44 
2014 34 34 17 34 36 35 39 22 52 
2015 34 36 32 33 18 44 32 38 39 
2016 27 35 24 29 14 25 21 25 40 
2017 24 29 24 27 17 25 21 24 25 
2018 21 26 18 27 21 26 12 16 25 
2019 19 16 28 16 18 24 6 19 22 
2020 12 18 11 12 8 12 7 10 19 
2021 14 16 17 21 10 8 9 14 14 
Note. Monitoring of NPS first commenced in 2010. DMT and PMA have been removed as NPS in this year’s report (i.e., 2010-2021 figures 
exclude DMT and PMA; refer to Chapter 8 for further information on DMT use among the sample). This has had a substantial impact on 
the percentage of the sample reporting ‘any’ NPS use in the past six months and means that the figures presented above will not align with 
those presented in previous EDRS reports. – Per cent suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 
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Table 17: Past six month use of NPS by drug type, nationally, 2010-2021 
 
 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 
 N=693 N=574 N=607 N=686 N=800 N=763 N=795 N=785 N=799 N=797 N=805 N=774 
% 
Phenethylamines^ 
7 14 12 20 20 18 13 12 9 7 6 7 
Any 2C substance~ 6 14 12 20 15 14 11 9 8 6 5 6 
NBOMe / / / / 9 7 4 5 2 2 1 1 
DO-x 1 1 0 - - 0 0 1 - - 0 0 
4-FA / / / / / / - - 0 0 0 0 
% Tryptamines^^ 0 2 - 1 1 0 1 1 1 2 1 2 
5-MeO-DMT - 5 - 1 1 - 1 1 1 2 1 2 
4-AcO-DMT / / / / / / - - / / / / 
% Synthetic 
cathinones 
19 18 11 9 8 8 3 5 4 5 1 1 
Mephedrone 16 13 5 6 5 3 1 1 - 1 0 - 
Methylone/bk 
MDMA 
/ 5 5 3 3 4 2 4 3 3 0 0 
MDPV/Ivory wave - 2 3 1 1 1 0 - 0 - 0 0 
Alpha PVP / / / / / / - - - - 0 0 
Other substituted 
cathinone 
/ / - 0 - - 0 - - / / / 
N-ethylpentylone / / / / / / / / / 0 0 0 
N-ethylhexedrone / / / / / / / / / 0 0 0 
N-ethylbutylone / / / / / / / / / / / 0 
% Piperazines 5 2 1 - - 0 0 - / / /  
BZP 5 2 1 - - 0 0 - / / / / 
% Dissociatives / / 1 2 2 2 3 2 0 2 1 2 
Methoxetamine 
(MXE) 
/ / 1 2 2 2 3 2 0 2 0 1 
% Other drugs that 
mimic the effects of 
dissociatives like 
ketamine 
/ / / / / / / / / / - 1 
% Plant-based 
NPS 
2 7 8 6 4 5 5 5 3 3 5 5 
Ayahuasca / / / / / 0 - 1 - 1 1 - 
Mescaline 2 4 2 3 2 2 2 3 2 2 2 3 
Salvia divinorum / 2 3 2 2 1 2 2 1 1 2 - 
Kratom           - 1 
LSA / 1 3 2 1 1 1 / / / / / 
Datura 0 - - 0 0 0 0 / / / / / 
% 
Benzodiazepines 
/ / / / / / 1 1 1 2 1 2 
Etizolam / / / / / / 1 1 1 1 0 1 
% Other drugs that 
mimic the effect of 
benzodiazepines 
/ / / / / / / / - 1 0 0 
% Synthetic 
cannabinoids 
/ 6 15 16 7 6 4 2 3 3 4 2* 
% Herbal high# / / 12 8 4 5 4 2 2 2 / / 
% Phenibut / / / / / / / / / 2 0 1 
% Other drugs 
that mimic the 
effect of opioids 
/ / / / / / / - - - 0 0 
% Other drugs 
that mimic the 
effect of ecstasy 
/ / / / / / / - 1 1 0 - 
% Other drugs 
that mimic the 
effect of 
/ / / / / / / 1 - 1 1 - 
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 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 
 N=693 N=574 N=607 N=686 N=800 N=763 N=795 N=785 N=799 N=797 N=805 N=774 
amphetamine or 
cocaine 
% Other drugs 
that mimic the 
effect of 
psychedelic drugs 
like LSD  
/ / / / / / / - 1 2 1 2 
Note. NPS first asked about in 2010. / not asked. ^In previous EDRS reports, PMA was included as a NPS under ‘phenethylamines’ and 
mescaline was included under both ‘phenethylamines’ and ‘plant-based NPS’. This year, PMA has been deleted as a NPS altogether, while 
mescaline was removed from ‘phenethylamines’ and is now only coded under ‘plant-based NPS’ – this means that the percentages reported 
for any phenethylamine NPS use (2010-2020) will not align with those presented in previous EDRS reports. ^^In previous EDRS reports, 
DMT was included as a NPS under ‘tryptamines’. This year, DMT has been removed as a NPS (refer to Chapter 8 for further information 
on DMT use among the sample), which means that the percentages reported for any tryptamine NPS use (2010-2020) will not align with 
those presented in previous EDRS reports. # The terms ‘herbal highs’ and ‘legal highs’ appear to be used interchangeably to mean drugs 
that have similar effects to illicit drugs like cocaine or cannabis but are not covered by current drug law scheduling or legislation. - not 
reported, due to small numbers (n≤5 but not 0). ~ In 2010 and between 2017-2019 three forms of 2C were asked about whereas between 
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Participants were asked about their recent (past 6 month) use 
of various other drugs, including non-prescribed use of 
pharmaceutical drugs (i.e., use of a prescribed drug obtained 
from a prescription in someone else’s name) and use of licit 
substances (e.g., alcohol, tobacco, e-cigarettes).  
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Non-Prescribed Pharmaceutical Drugs 
Codeine 
Before the 1 February 2018, people could access low-dose codeine products (<30mg, e.g., Nurofen 
Plus) over-the-counter (OTC), while high-dose codeine (≥30mg, e.g., Panadeine Forte) required a 
prescription from a doctor. On the 1 February 2018, legislation changed so that all codeine products, 
low- and high-dose, require a prescription from a doctor to access. 
Up until 2017, participants were only asked about use of OTC codeine for non-pain purposes. 
Additional items on use of prescription low-dose and prescription high-dose codeine were included in 
the 2018-2020 EDRS, however in 2021 participants were only asked about prescribed and non-
prescribed codeine use, regardless of whether it was low- or high-dose.  
Recent Use (past 6 months): In 2021, 24% of the national sample reported any recent use of codeine 
(25% in 2020; p=0.726). Fifteen per cent of the national sample had recently used prescribed codeine 
(15% in 2020; p=0.943), whereas 12% reported using non-prescribed codeine (12% in 2020).  
Recent Use for Non-Pain Purposes: Eight per cent of the sample reported using non-prescribed 
codeine for non-pain purposes (67% of those who had recently used non-prescribed codeine) (Figure 
36). 
Frequency of Use: Participants who had recently used non-prescribed codeine and commented 
(n=89) reported use on a median of 2 days (IQR=1-5) in the past six months, stable from 2020 (3 days; 
IQR=1-5; p=0.841).   
Pharmaceutical Opioids 
Recent Use (past 6 months): The per cent of participants reporting any past six month use of non-
prescribed pharmaceutical opioids (e.g., methadone, buprenorphine, oxycodone, morphine, fentanyl, 
excluding codeine) remained stable, from 9% in 2020 to 10% in 2021 (p=0.490) (Figure 36).  
Frequency of Use: Frequency of use remained low and stable in 2021 at a median of 2 days (IQR=1-
5; n=73) of non-prescribed pharmaceutical opioid use in the six months prior to interview (2 days in 
2020; IQR=1-4; p=0.297).     
Pharmaceutical Stimulants 
Recent Use (past 6 months): The per cent of participants reporting any recent non-prescribed 
pharmaceutical stimulant (e.g., dexamphetamine, methylphenidate, modafinil) use has steadily 
increased since the commencement of monitoring, from 17% in 2007 to 39% in 2020. An increase 
was observed in 2021, whereby 46% of the national sample reported recent use (p=0.004), signifying 
the highest percentage of recent use since monitoring commenced (Figure 36).  
Frequency of Use: Median days of use remained unchanged between 2020 and 2021 (5 days; 
IQR=2-12; n=353; 5 days in 2020; IQR=2-12; p=0.950).   
Quantity: Among those who reported recent use of non-prescribed pharmaceutical stimulants and 
responded (n=306), the median amount used in a ‘typical’ session was two pills/tablets (IQR=1-2; 2 
pills/tablets in 2020; IQR=1-3; p=0.013). Of those who reported recent use and responded (n=307), 
the median maximum amount used was two pills/tablets (IQR=1-4; maximum quantity of 
pharmaceutical stimulants not asked in 2020). 
Benzodiazepines 
Recent Use (past 6 months): Recent use of non-prescribed benzodiazepines has, for the most part, 
been increasing since monitoring began. In 2021, over one-third (35%) of the sample reported such 
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use, similar to 2020 (40%; p=0.054) (Figure 36). From 2019, participants were asked about non-
prescribed alprazolam use versus ‘other’ non-prescribed benzodiazepine use. Almost one-fifth (19%) 
of participants reported recent use of non-prescribed alprazolam, a significant decrease from 26% in 
2020 (p=0.001). Recent use of non-prescribed ‘other’ benzodiazepines remained stable, with over 
one-quarter (26%) reporting recent use in 2021 (28% in 2020; p=0.428).  
Frequency of Use: People who had recently used non-prescribed benzodiazepines and commented 
(n=148) reported a median of 3 days (IQR=1-6; 3 days in 2020; IQR=2-10; p=0.083) of non-prescribed 
alprazolam use and 3 days (IQR=2-10, n=201; 3 days in 2020; IQR=2-7; p=0.441) of non-prescribed 
‘other’ benzodiazepine use in the past six months, respectively.  
Antipsychotics 
Recent Use (past 6 months): Few participants reported any recent use of non-prescribed 
antipsychotics (7% in 2021; 5% in 2020; p=0.117) (Figure 36).  
Frequency of Use: A median of 5 days of use (IQR=1-65; n=55) was reported by participants who 
had recently used non-prescribed antipsychotics (3 days in 2020; IQR=1-8; p=0.950).  




Figure 36: Non-prescribed use of pharmaceutical drugs in the past six months, nationally, 2007-2021 
 
Note. Monitoring of pharmaceutical stimulants and benzodiazepines commenced in 2007, over-the-counter (OTC) codeine (low-dose codeine) in 2010, and pharmaceutical opioids and antipsychotics 
in 2013. Non-prescribed use is reported for prescription medicines. In February 2018, the scheduling for codeine changed such that low-dose codeine formerly available OTC was required to be 
obtained via a prescription. High-dose codeine was excluded from pharmaceutical opioids from 2018. The time series here represents non-prescribed low-dose codeine used for non-pain purposes 
(2010-2020) and non-prescribed codeine (low- and high-dose) for non-pain purposes (2021). Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; ***p<0.001.   
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Pharmaceutical Opioids 10 11 11 15 17 13 12 9 10
Codeine 8 12 14 13 11 16 18 21 11 6 9 8
Benzodiazepines 23 21 21 26 34 26 27 29 27 34 37 41 41 40 35
Pharmaceutical Stimulants 17 14 19 23 27 28 30 26 31 35 42 34 33 39 46
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Other Illicit Drugs 
Hallucinogenic Mushrooms 
Recent Use (past 6 months): Forty-five per cent of the national sample had used hallucinogenic 
mushrooms in the six months preceding interview, a significant increase from 30% in 2020 (p<0.001) 
(Figure 37).  
Frequency of Use: Frequency of use was infrequent in 2021 at a median of 2 days (IQR=1-4; n=346; 
2 days in 2020; IQR=1-4; p=0.151).  
MDA 
Recent Use (past 6 months): Recent use of MDA remained stable in 2021, with 5% of the national 
sample reporting any use of MDA in the six months preceding interview (6% in 2020; p=0.189) (Figure 
37).  
Frequency of Use: Frequency of use was infrequent at a median of 2 days (IQR=1-3, n=35) in 2021 
(no data were collected in 2020 on frequency of use).  
Substance with Unknown Contents 
Capsules: Capsules with unknown contents peaked in 2017, with 20% of participants reporting recent 
use. This has since decreased across recent years, with 6% of the national sample reporting past six-
month use in 2021, stable from 7% in 2020 (p=0.551) (Figure 37).  
Other Unknown Substances: Fifteen per cent of participants reported use of any substance with 
‘unknown contents’ in 2021 (18% in 2020; p=0.099) on a median of 1 day (IQR=1-4; questions on 
frequency of use were not asked in 2020).  
From 2019, we asked participants about their use more broadly of substances with ‘unknown 
contents’. These questions were asked by substance form, comprising capsules (as per previous 
years), pills, powder and crystal form. Of the 2021 sample, 5% reported using pills with unknown 
contents, 7% had recently used powder with unknown contents and 1% had recently consumed 
crystal with unknown contents. 
Quantity: From 2020, we asked participants about the average amount of pills and capsules used 
with unknown contents in the six months preceding interview. Of those who reported recent use and 
responded (n=37), the median ‘typical’ amount used in a session was one pill with unknown contents 
(IQR=1-3; 1 pill in 2020; IQR=1-2; p=0.001). Of those who reported recent use and responded (n=44), 
the median ‘typical’ amount used in a session was one capsule with unknown contents (IQR=1-2; 1 
capsule in 2020; IQR=1-2; p=0.073).  
Heroin  
Recent Use (past 6 months): Consistently small numbers have reported recent use of heroin (3% 
in 2021; 1% in 2020; p=0.117) (Figure 37).  
Frequency of Use: Participants reported a median of 2 days of use (IQR=1-5; n=20) in 2021, stable 
from 2020 (1 day; IQR=1-4; p=0.390).   
GHB/GBL/1,4 BD (Liquid E) 
Recent Use (past 6 months): Nine per cent of the national sample reported recent use of 
GHB/GBL/1,4 BD, a significant increase from 6% in 2020 (p=0.049) (Figure 37). 
Frequency of Use: GHB/GBL/1,4 BD was used on a median of 2 days in 2021 (IQR=1-6, n=67; 2 
days in 2020; IQR=1-6, p=0.975), indicating infrequent use.  
 




Figure 37: Past six month use of other illicit drugs, nationally, 2003-2021 
 
Note. Monitoring of capsules contents unknown commenced in 2013; note that in 2019, participants were asked more broadly about ‘substances contents unknown’ (with further ascertainment by 
form) which may have impacted the estimate for ‘capsules contents unknown’. Y axis reduced to 60% to improve visibility of trends. Significance for 2020 versus 2021 presented in figure; *p<0.050; 
**p<0.010; ***p<0.001.   
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
GHB/GBL/1,4 BD 11 10 9 8 7 7 4 6 7 7 6 5 5 8 7 6 5 6 9
MDA 19 15 9 7 6 4 5 7 12 10 12 12 13 11 14 14 10 6 5
Heroin 9 6 4 4 4 4 4 4 7 5 4 2 2 2 2 3 3 1 3
Capsules contents
 unknown 10 8 7 14 20 18 9 7 6
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Licit and Other Drugs 
Alcohol 
Recent Use (past 6 months): The majority of the national sample have reported recent alcohol use 
each year (96% in 2021; 98% in 2020; p=0.014) (Figure 38).  
Frequency of Use: People who had used alcohol reported a median of 48 days of use in the past six 
months (IQR=24-72; n=738; 45 days in 2020; IQR=20-72; p=0.366). Over three-quarters (78%) of 
consumers drank alcohol on a weekly or more frequent basis (75% in 2020; p=0.134); this includes 
4% who reported daily use (4% in 2020; p=0.430).  
Tobacco 
Recent Use (past 6 months): Whilst almost three-quarters (73%) of participants reported recent use 
in 2021, this was a significant decline from 83% reporting recent use in 2020 (p<0.001) (Figure 38).  
Frequency of Use: Median frequency of use reported by participants was 90 days (IQR=15-180; 
n=566; 120 days in 2020; IQR=24-180; p=0.074), with 39% of people who had recently used tobacco 
reporting daily use (42% in 2020; p=0.321). In 2021, daily use amongst those reporting any use was 
highest in the ACT sample (51%) and lowest in the WA sample (26%).  
E-cigarettes 
Recent Use (past 6 months): Almost three-fifths (58%) of the national sample reported any e-
cigarette use in the six months preceding interview, a significant increase from 39% in 2020 (p<0.001) 
(Figure 38). The highest per cent of recent use was observed in the NSW sample (85%) and the 
lowest per cent was observed in the NT sample (46%).  
Frequency of Use: Median days of use in the past six months also significantly increased, from 7 
days in 2020 (IQR=3-30) to 30 days in 2021 (IQR=7-120; n=444; p<0.001). Almost one-fifth (19%) of 
those who had recently used e-cigarettes reported use on a daily basis in the past six months, an 
increase from 8% in 2020 (p<0.001). 
Forms Used: Among those who had recently used e-cigarettes and responded (n=447), the majority 
(94%) reported using e-cigarettes containing nicotine, whereas 19% reported using e-cigarettes 
containing cannabis. Four per cent reported using e-cigarettes containing both nicotine and cannabis, 
and a further 4% reported using neither cannabis nor nicotine in 2021. 
Reason for Use: Of those who reported e-cigarette use and responded (n=446), over three-fifths 
(61%) reported that they did not use e-cigarettes as a smoking cessation tool in 2021.  
Nitrous Oxide 
Recent Use (past 6 months): The per cent of the sample reporting any recent use of nitrous oxide 
was stable in 2021 (49%) relative to 2020 (54%; p=0.073) (Figure 38). The national estimate belies 
high jurisdictional variation, ranging from 33% in the SA sample to 69% in the NSW sample in 2021. 
Frequency of Use: Frequency of use also remained stable, from 4 days (IQR=2-10) of use reported 
in 2020 to 4 days (IQR=2-10; n=378; p=0.121) of use reported in 2021, equivalent to less than monthly 
use.  
Quantity: Among those who reported recent use and responded (n=372), the median amount used 
in a ‘typical’ session was five bulbs (IQR=3-15; 8 bulbs in 2020; IQR=3-16.5; p=0.041). Of those who 
reported recent use and responded (n=371), the median maximum amount used was 10 bulbs 
(IQR=4-30; maximum quantity of nitrous oxide not asked in 2020).  
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Amyl Nitrite 
Amyl nitrite is an inhalant which is currently listed as a Schedule 4 substance in Australia (i.e., 
available only with prescription) yet is often sold under-the-counter in sex shops. Following a review 
by the Therapeutic Goods Administration, amyl nitrite was listed as Schedule 3 (i.e., for purchase 
over-the-counter) from 1 February 2020 when sold for human therapeutic purpose.  
Recent Use (past 6 months): Use of amyl nitrite has varied over the course of monitoring (Figure 
38). In 2021, two-fifths (40%) of participants reported any recent use of amyl nitrite, remaining stable 
from 43% in 2020 (p=0.289). There was variation in the per cent reporting any recent use between 
jurisdictions, from 21% in the WA sample to 55% in the ACT sample.  
Frequency of Use: Frequency of amyl nitrite use remained generally low and stable, with participants 













Figure 38: Past six month use of licit drugs, nationally, 2003-2021 
 
 
Note. Monitoring of e-cigarettes commenced in 2014. Significance for 2020 versus 2021 presented in figure; *p<0.050; **p<0.010; ***p<0.001.    
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Alcohol 93 95 97 96 98 97 97 97 98 96 97 98 97 97 97 98 97 98 96
Tobacco 75 74 75 75 74 72 80 78 86 83 77 77 82 83 87 85 83 83 73
E-cigarettes 34 34 26 28 34 40 39 58
Nitrous Oxide 26 27 25 22 22 20 19 20 25 21 25 23 26 36 42 50 53 54 49









































Participants were asked about various drug-related harms and 
associated behaviours, including hazardous alcohol use, non-fatal 
overdose following drug use, injecting drug use, drug treatment, 
mental health, crime and modes of purchasing drugs. It should be 
noted that the following data refer to participants’ understanding of 
these behaviours (e.g., may not necessarily represent medical 
diagnoses in the case of reporting on health conditions). 
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Polysubstance Use 
On the last occasion of ecstasy or related drug use, the most commonly used substances were 
alcohol (61%) and ecstasy (50%), followed by cannabis (42%) and hallucinogens/dissociatives (33%).  
The majority (88%; n=681) of the sample reported concurrent use of two or more drugs on the last 
occasion of ecstasy or related drug use. The most commonly used combinations of substances were 
alcohol and ecstasy (9%), followed by alcohol and cocaine (8%). Approximately one-in-fifteen 
participants reported using alcohol, ecstasy and cannabis (7%). Five per cent of the sample reported 
using ecstasy alone (Figure 39). 
Figure 39: Use of alcohol, ecstasy, cocaine, methamphetamine, cannabis, hallucinogens and 
dissociatives on the last occasion of ecstasy or related drug use, nationally, 2021: Most common drug 
pattern profiles  
 
 
Note. % calculated out of total EDRS 2021 sample. The horizontal bars represent the per cent of participants who reported use of each 
substance on their last occasion of ecstasy or related drug use; the vertical columns represent the per cent of participants who used the 
combination of drug classes represented by the orange circles. Drug use pattern profiles reported by ≤5 participants or which did not include 
any of the six substances depicted are not shown in the figure but are counted in the denominator. Halluc./Dissoc = 
hallucinogens/dissociatives (LSD, hallucinogenic mushrooms, amyl nitrite, DMT, ketamine and/or nitrous oxide); depressants (alcohol, 
GHB/GBL,1,4-BD, kava, opioids and/or benzodiazepines). Note that participants may report use of multiple substances within a class. Y 
axis reduced to 10% to improve visibility of trends.  
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Alcohol Use Disorders Identification Test  
The Alcohol Use Disorders Identification Test (AUDIT) was designed by the World Health 
Organization (WHO) as a brief screening scale to identify individuals with problematic alcohol use in 
the past 12 months.  
The mean score on the AUDIT for the total sample (including people who had not consumed alcohol 
in the past six months) was 12.9 (SD 7.0) in 2021 (13.1 (SD 6.4) in 2020; p<0.001). AUDIT scores 
are divided into four ‘zones’ which indicate risk level. Specifically, scores between 0-7 indicate low 
risk drinking or abstinence; scores between 8-15 indicate alcohol use in excess of low-risk guidelines; 
scores between 16-19 indicate harmful or hazardous drinking; and scores 20 or higher indicate 
possible alcohol dependence.  
Almost four in five (77%) participants obtained a score of eight or more (81% in 2020; p=0.025), 
indicative of hazardous use (Table 18). 
Table 18: AUDIT total scores and per cent of participants scoring above recommended levels, nationally, 
2010-2021 
 
 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 






























Score 8 or 
above (%) 
84 84 83 79 82 79 73 77 75 79 81 77* 
AUDIT 
zones 
Score 0-7:  
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Note. Monitoring of AUDIT first commenced in 2010. Total AUDIT score range is 0-40, with higher scores indicating greater likelihood of 
hazardous and harmful drinking. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
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Overdose Events 
Non-Fatal Overdose 
Previously, participants had been asked about their experience in the past 12-months of i) stimulant 
overdose, and ii) depressant overdose.  
From 2019, changes were made to this module. Participants were asked about the following in 2021, 
prompted by the definitions provided: 
• Alcohol overdose: experience of symptoms (e.g., reduced level of consciousness, 
respiratory depression, turning blue and collapsing) where professional assistance would have 
been helpful. 
• Stimulant overdose: experience of symptoms (e.g., nausea, vomiting, chest pain, tremors, 
increased body temperature, increased heart rate, seizure, extreme paranoia, extreme 
anxiety, panic, extreme agitation, hallucinations, excited delirium) where professional 
assistance would have been helpful. 
• Other drug overdose (not including alcohol or stimulant drugs): similar definition to 
above. Note that in 2019, participants were prompted specifically for opioid overdose but this 
was removed in 2020 as few participants endorsed this behaviour.  
 
It is important to note that events reported on for each drug type may not be unique given high rates 
of polysubstance use.  
For the purpose of comparison with previous years, we computed the per cent reporting any 
depressant overdose, comprising any endorsement of alcohol overdose, or other drug overdose 
where a depressant (e.g., opioid, GHB/GBL/1,4 BD, benzodiazepines) was listed. 
Non-Fatal Stimulant Overdose 
Sixteen per cent of the national sample reported experiencing a non-fatal stimulant overdose in the 
12 months preceding interview, stable relative to 2020 (18%; p=0.298) (Figure 40). 
The most common stimulants reported during the most recent non-fatal stimulant overdose in the past 
12 months comprised any form of ecstasy (66%; capsules: 32%; crystal: 18%; pills: 15% and powder: 
7%), cocaine (29%), any form of methamphetamine (18%) and pharmaceutical stimulants (15%). 
One-tenth (10%) reported that they had also consumed one or more additional drugs on the last 
occasion, most notably, any quantity of alcohol (76%; ≥5 standard drinks: 61%; ≤5 standard drinks: 
16%) and cannabis (35%). On the last occasion of experiencing a non-fatal stimulant overdose, 82% 
reported that they did not receive treatment or assistance. Of those that did report receiving treatment 
or assistance (n=22), most reported emergency department attendance (55%) and ambulance 
attendance (45%). 
Non-Fatal Depressant Overdose 
Alcohol: Fifteen per cent of the national sample reported a non-fatal alcohol overdose in the 12 
months preceding interview on a median of one occasion (IQR=1-4). This represents a significant 
decrease from those experiencing a non-fatal alcohol overdose in 2020 (21%; p=0.008). Of those 
who had experienced an alcohol overdose in the past year (n=119), the majority (93%) reported not 
receiving treatment on the last occasion. Of those who reported receiving treatment (n=10), the 
majority reported hospital emergency department admission (5%), with smaller numbers reporting 
ambulance attendance (n≤5). 
Any depressant (including alcohol): Almost one-fifth (19%) of participants reported that they had 
experienced a non-fatal depressant overdose in the past 12 months, stable relative to 2020 (23%; 
p=0.065) (Figure 40).  
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Of those who had experienced any depressant overdose in the past 12 months (n=144), the majority 
reported alcohol as the most common depressant drug (83%), with a smaller per cent reporting 
benzodiazepines (11%), and GHB/GBL/1,4 BD (8%). Five per cent reported a non-fatal overdose due 
to an opioid (including heroin and pharmaceutical opioids).  
Figure 40: Past 12 month non-fatal stimulant and depressant overdose, nationally, 2007-2021 
 
 
Note. Past year stimulant and depressant was first asked about in 2007. In 2019, items about overdose were revised, and changes relative 
to 2018 and earlier may be a function of greater nuance in capturing depressant events. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 
2021. 
  
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Past year stimulant 10 13 8 12 22 18 26 20 20 19 26 25 22 18 16
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Injecting Drug Use and Associated Risk Behaviours  
For the past several years, approximately one in ten participants have reported ever injecting drugs 
(11% in 2021, 8% in 2020; p=0.146). The per cent who reported injecting drugs in the past month 
over this period has been low, though stable, with 2% reporting past month injection in 2021 (1% in 
2020) (Figure 41).  
Figure 41: Lifetime and past month drug injection, nationally, 2003-2021 
 
  
Note. Items assessing whether participants had injected drugs in the past month were first asked in 2016. *p<0.050; **p<0.010; ***p<0.001 
for 2020 versus 2021. 
 
Drug Treatment 
A nominal per cent reported currently receiving drug treatment in 2021 (3%), stable compared with 
2020 (3% in 2020; p=0.381). Of those who had reported being in treatment (n=27), the majority 
reported drug counselling as their main form of treatment (70% of those who reported receiving 
treatment in 2021 versus 86% in 2020).  
  
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Lifetime 30 23 19 20 21 18 16 16 19 16 13 10 8 10 8 8 11 8 11
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Sexual Health Behaviours 
In 2021, 82% of the sample reported some form of sexual activity in the past four weeks. Given the 
sensitive nature of these questions, participants were given the option of self-completing this section 
of the interview (if interview undertaken face-to-face). 
Of those who had engaged in sexual activity in the past four weeks and who responded (n=612), 86% 
reported using alcohol and/or other drugs prior to or while engaging in sexual activity. Of those who 
had engaged in sexual activity in the past four weeks and responded (n=608), 11% reported that their 
use of alcohol and/or other drugs had impaired their ability to negotiate their wishes during sex. 
Furthermore, of those who had engaged in sexual activity in the past four weeks and who responded 
(n=608), 22% reported penetrative sex without a condom where they did not know the HIV status of 
their partner (Table 19). 
Of those who commented (n=759), over one-third (36%) of the sample reported having a sexual health 
check-up in the six months prior to interview. A further 40% had done so more than six months ago, 
and 24% had never had a sexual health check-up. Of the total sample, 78% reported that they had 
never received a positive diagnosis for a sexually transmitted infection (STI); 3% had received a 
positive diagnosis in the past six months; and 19% had received a positive diagnosis over six months 
ago.  
Of those who commented (n=759), over half (57%) the sample reported having ever had a test for 
human immunodeficiency virus (HIV) (24% in the past six months; 33% more than six months ago). 
The majority of the sample (99%) had never been diagnosed with HIV.   
Table 19: Sexual health behaviours, nationally and jurisdictionally, 2021 
 
Note. Don’t know and did not respond responses excluded. The wording of these questions changed in 2021, thus comparisons to previous 
years are not provided. #Due to the sensitive nature of these items, there is missing data for some participants who chose not to respond.  
 National NSW ACT VIC TAS SA WA NT QLD 
Of those who responded: N=749 N=96 N=98 N=100 N=99 N=88 N=99 N=98 N=71 
% Any sexual activity in 

















Of those who responded#: n=612 n=74 n=82 n=78 n=82 n=70 n=83 n=88 n=55 
% Drugs and/or alcohol 
used prior to or while 
engaging in sexual activity 
86 89 88 95 82 84 76 89 84 
Of those who responded#: n=608 n=74 n=82 n=78 n=82 n=70 n=80 n=87 n=55 
% Drugs and/or alcohol 
impaired their ability to 
negotiate their wishes during 
sexual activity 
11 12 7 - 11 10 16 15 - 
Of those who responded#: n=608 n=71 n=82 n=78 n=81 n=73 n=83 n=85 n=55 
% Had penetrative sex 
without a condom and did 
not know HIV status of 
partner 
22 23 27 14 16 16 10 42 25 
Of the total sample (past 
six months): n=759 n=95 n=98 n=100 n=98 n=93 n=95 n=98 n=72 
% Had a HIV test 24 25 32 32 18 25 16 30 13 
% Diagnosed with HIV - 0 0 - 0 0 - 0 0 
% Had a sexual health 
check  36 29 45 39 39 33 30 45 27 
% Diagnosed with a sexually 
transmitted infection 3 - - - - - - - - 
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Mental Health  
Almost three-fifths (58%) of the national sample self-reported that they had experienced a mental 
health problem in the preceding six months (other than drug dependence), a significant increase from 
2020 (52%; p=0.017) (Figure 42). Of those who reported a mental health problem and commented 
(n=430), the most common mental health problem reported was anxiety (71%), followed by 
depression (62%) and post-traumatic stress disorder (PTSD) (14%). Of those that reported 
experiencing a mental health problem (n=442), 60% (60% in 2020; p=0.947) reported seeing a mental 
health professional during the past six months (35% of the total sample). Of those who attended a 
mental health professional in 2021 (n=267), 54% reported being prescribed medication for their 
mental health problem (50% in 2020; p=0.449). 




Note. Questions about treatment seeking were first asked in 2008. The combination of the per cent who report treatment seeking and no 
treatment is the per cent who reported experiencing a mental health problem in the past six months. *p<0.050; **p<0.010; ***p<0.001 for 
2020 versus 2021. 
Driving 
Of the national sample, the majority (84%) had driven a car, motorcycle or other vehicle in the last six 
months. One-quarter (25%) of the sample reported driving while over the perceived legal limit of 
alcohol (28% of those who had driven in the past six months) and two-fifths (39%) reported driving 
within three hours of consuming an illicit or non-prescribed drug in the last six months (46% of those 
who had driven in the past six months) (Table 20). Among those who reported driving within three 
hours of consuming an illicit or non-prescribed drug in the last six months, cannabis was the most 
common drug used prior to driving (71%), followed by cocaine (21%) and pharmaceutical stimulants 
(12%). Smaller numbers reported the use of crystal methamphetamine (10%) and ecstasy capsules 
(7%). One-tenth (10%) of the national sample reported that they had been tested for drug driving by 
the police roadside drug testing service, and 31% reported that they had been breath tested for 
alcohol by the police roadside testing service in the six months prior to interview. 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
No treatment seeking 13 15 11 12 11 14 13 15 16 18 17 24 21 23
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Table 20: Self-reported driving behaviour in the last six months, nationally and by jurisdiction, 2021 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=774 N=99 N=100 N=100 N=101 N=100 N=100 N=100 N=73 
% Driven in the last six 
months 84 75 88 77 91 77 90 87 85 
% Driven over the legal 
alcohol limit in the last six 
months 
25 22 27 18 24 23 31 31 23 
% Driven within three hours 
of consuming illicit drug(s) 
last six months 
39 34 43 36 31 38 44 36 49 
% Tested for drug driving by 
police roadside drug testing 
last six months 
10 - 14 - 15 11 13 7 8 
% Breath tested for alcohol 
by police roadside testing 
last six months 
31 25 39 15 37 31 54 25 23 
Note: Questions about driving behaviour were not asked in 2020. Computed out of the total sample. 
 
Figure 43: Self-reported driving in the past six months over the (perceived) legal limit for alcohol and 
three hours following illicit drug use, nationally, 2007-2021 
 
  
Note. Computed of the entire sample. Questions about driving behaviour were first asked about in 2007. Questions about driving behaviour 
were not asked in 2014 or 2020.  
 
  
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Driven in past 6 months 77 79 79 77 75 76 74 82 78 81 83 81 84
Drink driving 29 31 34 35 32 31 25 33 29 29 24 26 24
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Crime  
Past month self-reported criminal activity has fluctuated over time, with 36% reporting ‘any’ crime in 
the past month, stable relative to 2020 (33%; p=0.128). Drug dealing and property crime remained 
the two main forms of criminal activity, with both remaining stable in 2021, relative to 2020. Almost 
one-quarter (23%) reported drug dealing in 2021 (20% in 2020; p=0.225) and almost one-fifth (18%) 
reported property crime in 2021 (15% in 2020; p=0.190) (Figure 44). Six per cent reported being the 
victim of a crime involving violence (e.g., assault) in 2021 (5% in 2020; p=0.840). 
One-tenth (10%) of the 2021 national sample reported having been arrested in the 12 months 
preceding interview, stable relative to 2020 (8%; p=0.083). Of those who commented (n=77), the main 
reasons for arrest in 2021 were violent crime (23%), use/possession of drugs (21%) and property 
crime (17%).  
Four per cent of the national sample reported a lifetime history of imprisonment in 2021, stable relative 
to 2020 (2%; p=0.053).  




Figure 44: Self-reported criminal activity in the past month, nationally, 2003-2021 
 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Property crime 7 6 5 8 11 9 15 14 18 17 17 15 15 13 17 20 21 15 18
Drug dealing 33 19 20 24 23 24 29 24 25 27 21 26 26 28 34 32 32 20 23
Fraud 2 2 3 3 1 3 3 2 4 3 3 3 3 3 2 3 4 2 2
Violent crime 2 2 2 3 3 2 4 5 6 5 3 4 3 4 3 4 3 3 3
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Modes of Purchasing Illicit or Non-Prescribed Drugs  
In interviewing and reporting, ‘online sources’ were defined as either surface or darknet marketplaces.  
In 2021, the most popular means of arranging the purchase of illicit or non-prescribed drugs in the 12 
months preceding interview was face-to-face (72%), a significant increase relative to 2020 (67%; 
p=0.040). This was closely followed by social networking applications (e.g., Facebook, Wickr, 
WhatsApp, Snapchat, Grindr, Tinder) (71%; 75% in 2020; p=0.064). It is important to re-iterate that 
this refers to people arranging the purchase of illicit or non-prescribed drugs. This captures 
participants who messaged friends or known dealers on Facebook Messenger or WhatsApp, for 
example, to organise the purchase of illicit or non-prescribed drugs, which may have then been picked 
up in person. In 2021, significantly fewer participants reported arranging the purchase of illicit or non-
prescribed drugs via text messaging (39%; 48% in 2020; p=0.001) and phone call (28%; 35% in 2020; 
p=0.003). Seven per cent had obtained drugs via the darknet market in the past year (7% in 2020; 
p=0.887) and 4% had purchased drugs on the surface web (6% in 2020; p=0.050) (Table 21).  
When asked about how they had received illicit drugs on any occasion in the last 12 months, the 
majority of participants reported face-to-face (98%), which was stable relative to 2020 (96%; p=0.059). 
In 2021, a decrease was observed in those receiving illicit drugs via a collection point (10%; 20% in 
2020; p<0.001) (collection point defined as a predetermined location where a drug will be left for later 
collection). A significant decrease was also observed in those receiving illicit drugs via post (8%; 12% 
in 2020; p=0.015) (Table 21).   
The majority of participants in 2021 reported obtaining illicit drugs from a 
friend/relative/partner/colleague (83%; 84% in 2020; p=0.957), followed by a known dealer/vendor 
(66%; 68% in 2020; p=0.572). Significantly fewer participants reported obtaining illicit drugs from an 
unknown dealer/vendor in 2021 (30%; 37% in 2020; p=0.004) (Table 21).    
In 2021, a minority of participants reported to have sold illicit drugs on the surface web or darknet 
market, with 2% reporting selling drugs online in the 12 months preceding interview (3% in 2020; 
p=0.045). Almost three-fifths (59%) reported they had ever obtained illicit drugs through someone 
who had purchased them on the surface web or darknet market, with 39% doing so in the last 12 
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Table 21: Means of purchasing illicit drugs in the past 12 months, nationally and by jurisdiction, 2020-
2021 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 n=799 n=774 n=98 n=100 n=99 n=98 n=98 n=100 n=99 n=72 
 2020 2021         
% Purchasing 
approaches in 
the last 12 
months^ 
n=799 n=764         
Face-to-face 67 72* 64 63 52 70 83 90 86 68 
Surface web 6 4 7 - - - - - - - 




75 71 80 56 88 66 72 73 66 61 
Text messaging 48 39** 34 48 20 37 54 35 55 31 
Phone call 35 28** 29 33 19 27 35 21 40 21 
Grew/made my 
own 
4 4 - 11 0 - - - - - 
Other 1 0* 0 0 0 0 0 0 0 0 
% Means of 
obtaining drugs 
in the last 12 
months^~ 
n=803 n=761 n=99 n=100 n=100 n=102 n=100 n=100 n=100 n=73 
Face-to-face 96 98 95 95 98 92 97 97 97 96 
Collection point 20 10*** 11 9 - 9 20 - 10 8 
Post 12 8* 13 8 10 7 6 10 - - 
% Source of 
drugs in the last 
12 months^ 
n=789 n=763 n=98 n=99 n=99 n=96 n=98 n=100 n=100 n=73 
Friend/relative/ 
partner/colleague 
84 83 82 76 73 94 89 88 85 81 
Known 
dealer/vendor 
68 66 74 72 75 68 78 50 51 64 
Unknown 
dealer/vendor 
37 30** 38 19 33 22 33 29 34 34 
Note. - not reported, due to small numbers (n≤5 but not 0). ^ participants could endorse multiple responses. #This refers to people arranging 
the purchase of illicit or non-prescribed drugs. This captures participants who messaged friends or known dealers on Facebook Messenger 
or WhatsApp, for example, to organise the purchase of illicit or non-prescribed drugs, which may have then been picked up in person. ~ 
The face-to-face response option in 2021 was combined by those responding, 'I went and picked up the drugs’, ‘The drugs were dropped 
off to my house by someone’ and/or ‘Was opportunistic – I arranged and collected at the same time (e.g., at an event/club).’ *p<0.050; 
**p<0.010; ***p<0.001 for 2020 versus 2021. 
 
 
 
 
 
 
 
